cpd_id,master_cpd_id,cpd_name,broad_cpd_id,top_test_conc_umol,cpd_status,inclusion_rationale,gene_symbol_of_protein_target,target_or_activity_of_compound,source_name,source_catalog_id,cpd_smiles
16-BETA-BROMOANDROSTERONE,411726,16-BETA-BROMOANDROSTERONE,BRD-K98404142,37.0,probe,pilot-set,,dehydroepiandrosterone (DHEA) analog,Sigma-Aldrich,B9392,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1C[C@H](Br)C2=O
"1S,3R-RSL-3",609060,"1S,3R-RSL-3",BRD-K23853216,33.0,probe,pilot-set,GPX4,synthetic lethal with HRAS in engineered cells; inhibitor of GPX4,Columbia University,,COC(=O)[C@H]1Cc2c([nH]c3ccccc23)[C@@H](N1C(=O)CCl)c1ccc(cc1)C(=O)OC
3-CL-AHPC,660796,3-CL-AHPC,BRD-A09890259,66.0,probe,outreach,NR0B2,binder of nuclear receptor SHP,Sanford-Burnham Medical Research Institute,,OC(=O)\C=C\c1ccc(c(Cl)c1)-c1ccc(O)c(c1)C12C[C@H]3C[C@H](C[C@H](C3)C1)C2
968,660080,968,BRD-A43210826,66.0,probe,lit-search,GLS,inhibitor of glutaminase,Specs,AG-690/36107028,CN(C)c1ccc(cc1Br)C1Nc2ccc3ccccc3c2C2=C1C(=O)CC(C)(C)C2
A-804598,661033,A-804598,BRD-K76894955,66.0,probe,lit-search,P2RX7,inhibitor of purinergic receptor P2X,Tocris Bioscience,4473,C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1
AA-COCF3,411724,AA-COCF3,BRD-K07303502,270.0,probe,pilot-set,FAAH;PLA2G4A;PLA2G4B;PLA2G4C;PLA2G4D,inhibitor of cytosolic phospholipase A2; inhibitor of fatty acid amide hydrolase,Cayman,62120,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)C(F)(F)F
ABIRATERONE,660363,ABIRATERONE,BRD-K50071428,17.0,FDA,std-of-care,CYP17A1,"inhibitor of 17 alpha-hydroxylase and C17,20 lyase",Selleck,S1123,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1
ABT-199,666541,ABT-199,BRD-K62391742,66.0,clinical,lit-search,BCL2,inhibitor of BCL2,Active Biochem,A-1231,CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1
ABT-737,411738,ABT-737,BRD-K56301217,37.0,clinical,pilot-set,BCL2;BCL2L1;BCL2L2,"inhibitor of BCL2, BCL-xL, and BCL-W",Toronto Research Chemicals,A112550,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1
AC55649,375487,AC55649,BRD-K93176058,33.0,probe,chromatin;pilot-set,RARB,agonist of retinoic acid receptor beta,ChemBridge Corporation,5308535,CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O
AFATINIB,606135,AFATINIB,BRD-K66175015,66.0,clinical,kinome,EGFR;ERBB2,inhibitor of EGFR and HER2,Selleck,S1011,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1
AGK-2,411716,AGK-2,BRD-K32536677,33.0,probe,chromatin;pilot-set,SIRT2,inhibitor of sirtuin 2,ChemBridge Corporation;Tocris Bioscience,5857140;3233,Clc1ccc(Cl)c(c1)-c1ccc(\C=C(/C#N)C(=O)Nc2cccc3ncccc23)o1
ALISERTIB,636711,ALISERTIB,BRD-K75295174,66.0,clinical,CTEP;kinome,AURKA;AURKB,inhibitor of aurora kinases A and B,Selleck,S1133,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O
ALISERTIB:NAVITOCLAX (2:1 MOL/MOL),660282,ALISERTIB:NAVITOCLAX (2:1 MOL/MOL),BRD-M07476339,50.0,probe,combination,AURKA;AURKB;BCL2;BCL2L1;BCL2L2,"inhibitor of aurora kinases A and B;inhibitor of BCL2, BCL-xL, and BCL-W",,,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
ALVOCIDIB,687720,ALVOCIDIB,BRD-K68682020,66.0,clinical,CTEP;kinome,CDK1;CDK2;CDK4;CDK6,inhibitor of cyclin-dependent kinases,Selleck,S1230,CN1CC[C@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl
AM-580,58455,AM-580,BRD-K06854232,530.0,probe,chromatin;pilot-set,RARA,agonist of retinoic acid receptor alpha,Sigma-Aldrich,A8843,CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O
APICIDIN,61097,APICIDIN,BRD-K64606589,33.0,probe,chromatin;outreach,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",Fermentek Ltd,Fermentek-AC001,CC[C@@H](C)[C@@H]1NC(=O)[C@H](Cc2cn(OC)c3ccccc23)NC(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C1=O
AT-406,710154,AT-406,BRD-K02834582,66.0,probe,lit-search;synthesis,XIAP,SMAC mimetic; inhibitor of inhibitor of apoptosis proteins (IAPs),Selleck,S2754,CNC(C)C(=O)NC1CN(CCC2CCC(N2C1=O)C(=O)NC(c3ccccc3)c4ccccc4)C(=O)CC(C)C
AT13387,688229,AT13387,BRD-K58435339,66.0,clinical,CTEP,HSP90AA1,inhibitor of HSP90,Selleck,S1163,CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O
AT7867,660409,AT7867,BRD-K12040459,66.0,probe,chromatin;kinome,AKT1;AKT2;AKT3;RPS6KB2,inhibitor of AKT1/2/3 and S6K,Selleck,S1558,Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1
AUSTOCYSTIN D,416775,AUSTOCYSTIN D,BRD-K25987073,37.0,probe,pilot-set,,natural product; inducer of DNA damage,Harvard Medical School,,CC(C)(O)CCc1ccc(O)c2c1oc1cc3O[C@H]4OC=C[C@@]4(O)c3c(O)c1c2=O
AVICIN D,688975,AVICIN D,BRD-A15100685,66.0,probe,outreach,,natural product,MD Anderson Cancer Center,,CC1O[C@@H](OCC2O[C@@H](O[C@H]3CC[C@@]4(C)C(CC[C@]5(C)C4CC=C4C6CC(C)(C)[C@H](C[C@@]6([C@H](O)C[C@@]54C)C(=O)O[C@@H]4OC(CO)[C@@H](O)[C@@H](O)[C@@H]4O[C@@H]4OC(C)[C@H](O[C@@H]5O[C@@H](CO)[C@H](O)[C@@H]5O)[C@@H](O[C@@H]5OC(CO)[C@@H](O)[C@@H](O)[C@@H]5O)[C@@H]4O)OC(=O)C(\CO)=C\CC[C@](C)(O[C@@H]4OC(C)[C@@H](OC(=O)C(\CO)=C\CCC(C)(O)C=C)[C@@H](O)[C@@H]4O)C=C)C3(C)C)[C@@H](NC(C)=O)[C@H](O)[C@@H]2O)[C@@H](O[C@@H]2OC[C@@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H]1O
AVRAINVILLAMIDE,411856,AVRAINVILLAMIDE,BRD-K10466330,33.0,probe,pilot-set,NPM1,natural product; inhibitor of nucleophosmin,Harvard University,,CC1(C)Oc2ccc3C4=C[C@@]56NC(=O)[C@]7(CCCN7C5=O)C[C@H]6C(C)(C)C4=[N+]([O-])c3c2C=C1
AXITINIB,348990,AXITINIB,BRD-K29905972,66.0,FDA,kinome,FLT1;FLT3;KDR;KIT;PDGFRA;PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta",Selleck,S1005,CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1
AZ-3146,660087,AZ-3146,BRD-K59146805,66.0,probe,lit-search,TTK,inhibitor of TTK protein kinase,Selleck,S2731,COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1
AZACITIDINE,26874,AZACITIDINE,BRD-K03406345,66.0,FDA,CTEP;std-of-care,DNMT1,inhibitor of DNA methyltransferase,Selleck,S1782,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
AZD1480,660306,AZD1480,BRD-K65928735,66.0,clinical,CTEP;kinome,JAK1;JAK2,inhibitor of Janus kinases 1 and 2,Selleck,S2162,C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1
AZD4547,660325,AZD4547,BRD-K28392481,66.0,clinical,lit-search,FGFR1;FGFR2;FGFR3,inhibitor of fibroblast growth factor receptors,Active Biochem,A-1174,COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1
AZD6482,639390,AZD6482,BRD-K58772419,66.0,clinical,kinome,PIK3CB;PIK3CD,inhibitor of PI3K catalytic subunits beta and delta,Selleck,S1462,C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1
AZD7545,411814,AZD7545,BRD-K52836380,74.0,probe,kinome;pilot-set,PDK2,inhibitor of pyruvate dehydrogenase kinase 2,WuXi AppTec;WuXi AppTec,TH02357-029-A;TH02357-029-B,CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c1
AZD7762,660777,AZD7762,BRD-K86525559,66.0,clinical,kinome,CHEK1;CHEK2,inhibitor of checkpoint kinases 1 and 2,Selleck,S1532,NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1
AZD8055,609639,AZD8055,BRD-K69932463,66.0,clinical,kinome,MTOR,inhibitor of mTOR,Selleck,S1555,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C
B02,122255,B02,BRD-K10882151,130.0,probe,chromatin;pilot-set,RAD51,inhibitor of RAD51,Vitas-M Laboratory Ltd.,STK856883,O=c1n(Cc2ccccc2)c(\C=C\c2cccnc2)nc2ccccc12
BAFILOMYCIN A1,467037,BAFILOMYCIN A1,BRD-K86787118,0.33,probe,outreach,ATP6V0A1,inhibitor of the vacuolar-type H+-ATPase,EMD Biosciences,BML-CM110-0100,CO[C@H]1\C=C\C=C(C)\C[C@@H](C)[C@H](O)[C@H](C)\C=C(C)\C=C(OC)\C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@H]1C[C@@H](O)[C@H](C)[C@H](O1)C(C)C
BARASERTIB,601923,BARASERTIB,BRD-K63923597,66.0,clinical,kinome,AURKB,inhibitor of aurora kinase B,Selleck,S1147,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1
BARDOXOLONE METHYL,660318,BARDOXOLONE METHYL,BRD-K59437938,66.0,clinical,lit-search,,electrophilic inducer of the NFE2L2-KEAP1 pathway,Axon Medchem,1772,COC(=O)[C@@]12CCC(C)(C)C[C@@H]1[C@@H]1C(=O)C=C3[C@]4(C)C=C(C#N)C(=O)C(C)(C)[C@H]4CC[C@]3(C)[C@@]1(C)CC2
BAX CHANNEL BLOCKER,18311,BAX CHANNEL BLOCKER,BRD-A18763547,33.0,probe,pilot-set,BAX,inhibitor of BAX-mediated mitochondrial cytochrome c release,Maybridge,RJC01737,OC(CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12
BCL-LZH-4,688516,BCL-LZH-4,BRD-A68258842,66.0,probe,lit-search;synthesis,,"inhibitor of BCL2, BCL-xL, and MCL1",Broad Institute of MIT and Harvard,,COc1ccc(cc1)C1C(C(=O)Nc2ccccc2)=C(C)N=c2s\c(=C/c3cn(Cc4ccccc4)c4ccccc34)c(=O)n12
BEC,60679,BEC,BRD-K53792571,270.0,probe,pilot-set,ARG1;ARG2,inhibitor of arginase I and II,EMD Biosciences,197900,N[C@H](CSCCB(O)O)C(O)=O
BELINOSTAT,60225,BELINOSTAT,BRD-K17743125,66.0,clinical,chromatin;CTEP,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",Selleck,S1085,ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1
BENDAMUSTINE,374755,BENDAMUSTINE,BRD-K17068645,66.0,FDA,std-of-care,,DNA alkylator,Selleck,S1212,Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl
BETULINIC ACID,23256,BETULINIC ACID,BRD-K45401373,66.0,probe,chromatin;lit-search,,natural product; inhibitor of specificity protein 1 transcription factor in cells,Tocris Bioscience,3906,CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O
BEXAROTENE,374747,BEXAROTENE,BRD-K92441787,66.0,FDA,chromatin;std-of-care,RXRA;RXRB;RXRG,inhibitor of retinoid X receptors,LC Laboratories,B-2422,Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C
BI-2536,347813,BI-2536,BRD-K64890080,33.0,clinical,kinome;pilot-set,PLK1,inhibitor of polo-like kinase 1 (PLK1),Selleck,S1109,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O
BIBR-1532,417982,BIBR-1532,BRD-K04623885,270.0,probe,chromatin;pilot-set,TERT,inhibitor of telomerase reverse transcriptase,Selleck,S1186,C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1
BIRB-796,660412,BIRB-796,BRD-K74065929,66.0,probe,kinome,MAPK11;MAPK11;MAPK14,inhibitor of p38 MAPK,Selleck,S1574,Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C
BIRINAPANT,660778,BIRINAPANT,BRD-K18589165,66.0,clinical,CTEP;lit-search,DIABLO;XIAP,SMAC mimetic; inhibitor of inhibitor of apoptosis proteins (IAPs),Active Biochem,A-1901,CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1cc2c(C[C@@H]3C[C@H](O)CN3C(=O)[C@H](CC)NC(=O)[C@H](C)NC)cc(F)cc2[nH]1
BIX-01294,53705,BIX-01294,BRD-K26818574,33.0,probe,chromatin;pilot-set,EHMT2,inhibitor of G9a histone methyltransferase,Broad Institute of MIT and Harvard,,COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1
BLEBBISTATIN,50140,BLEBBISTATIN,BRD-A75817871,130.0,probe,pilot-set,MYH1;MYH2,inhibitor of myosin II ATPases,Cayman,13165,Cc1ccc2N=C3N(CCC3(O)C(=O)c2c1)c1ccccc1
BLEOMYCIN A2,639531,BLEOMYCIN A2,BRD-A42083487,66.0,FDA,std-of-care,,inducer of DNA damage,Selleck;Calbiochem,S1214;203401-10MG,C[C@@H](O)[C@@H](NC(=O)[C@H](C)[C@@H](O)[C@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)C(O[C@H]1O[C@H](CO)[C@H](O)[C@@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCC[S+](C)C
BMS-195614,660228,BMS-195614,BRD-K45935533,66.0,probe,chromatin;lit-search,RARA;RARB;RARG,antagonist of retinoic acid receptors,Tocris Bioscience,3660,CC1(C)CC=C(c2cnc3ccccc3c2)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O
BMS-270394,660321,BMS-270394,BRD-K04905989,66.0,probe,chromatin;lit-search,RARG,antagonist of retinoic acid receptor gamma,Axon Medchem,1173,CC1(C)CCC(C)(C)c2cc(ccc12)[C@@H](O)C(=O)Nc1ccc(cc1F)C(O)=O
BMS-345541,622911,BMS-345541,BRD-K13566078,66.0,probe,kinome,IKBKB,inhibitor of IKK-2,Axon Medchem,Axon 1731,Cc1cnc2c(NCCN)nc3ccc(C)cc3n12
BMS-536924,411859,BMS-536924,BRD-K34581968,37.0,probe,pilot-set,IGF1R;INSR,inhibitor of insulin-like growth factor 1 receptor (IGF1R) and insulin receptor (INSR),Selleck,S1012,Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1
BMS-754807,417981,BMS-754807,BRD-K13049116,33.0,probe,pilot-set,IGF1R,inhibitor of insulin-like growth factor 1 receptor and insulin receptor,Active Biochem,A-1013,C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1
BORTEZOMIB,411737,BORTEZOMIB,BRD-K88510285,0.13,FDA,CTEP;pilot-set;std-of-care,PSMB1;PSMB2;PSMB5;PSMD1;PSMD2,inhibitor of 26S proteasome,Toronto Research Chemicals;Selleck,B675700;S1013,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O
BOSUTINIB,660346,BOSUTINIB,BRD-K90746395,66.0,FDA,kinome,ABL1;SRC,inhibitor of SRC and ABL1,Selleck,S1014,COc1cc(Nc2cc(nc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl
BRD-A02303741,659371,BRD-A02303741,BRD-A02303741,55.0,probe,chromatin;lit-search;synthesis,DOT1L,inhibitor of histone methyltransferases,Broad Institute of MIT and Harvard,,CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H](C(O)[C@H]1O)n1cnc2c(N)ncnc12
BRD-A02303741:CARBOPLATIN (1:1 MOL/MOL),660271,BRD-A02303741:CARBOPLATIN (1:1 MOL/MOL),BRD-M48845972,66.0,probe,combination,DOT1L,inhibitor of histone methyltransferases;inducer of DNA damage,,,O=C1O[Pt]OC(=O)C11CCC1.CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12
BRD-A02303741:NAVITOCLAX (2:1 MOL/MOL),660268,BRD-A02303741:NAVITOCLAX (2:1 MOL/MOL),BRD-M76874421,50.0,probe,combination,DOT1L;BCL2;BCL2L1;BCL2L2,"inhibitor of histone methyltransferases;inhibitor of BCL2, BCL-xL, and BCL-W",,,CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
BRD-A05715709,660342,BRD-A05715709,BRD-A05715709,66.0,probe,outreach,IDH1,putative inhibitor of IDH1 R132H,Broad Institute of MIT and Harvard,,Cc1ccccc1C(N(C(=O)Cc1ccncc1)c1cccc(F)c1)C(=O)NC1CCCCC1
BRD-A71883111,660145,BRD-A71883111,BRD-A71883111,33.0,probe,lit-search,IDH1,putative inhibitor of IDH1 R132H,Broad Institute of MIT and Harvard,,Fc1cccc(c1)N(C(C(=O)NC1CCCCC1)c1ccccc1Cl)C(=O)Cc1cccs1
BRD-A86708339,687769,BRD-A86708339,BRD-A86708339,66.0,probe,outreach,,screening hit,Dana Farber Cancer Institute,,Cc1ccc(cc1)C(NC(=O)c1ccccc1)c1ccc2cccnc2c1O
BRD-A94377914,61724,BRD-A94377914,BRD-A94377914,33.0,probe,chromatin;outreach,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",Stanley Center for Psychiatric Research at the Broad Institute,,CN1CCCCC1NC(=O)[C@H](CCCCCC(C)=O)C(=O)Nc1nc(cs1)-c1ccccc1
BRD-K01737880,438345,BRD-K01737880,BRD-K01737880,66.0,probe,outreach,,screening hit,Broad Institute of MIT and Harvard,,COc1ccc(NC(=O)Nc2ccc3O[C@@H](CN(C)Cc4ccc5OCOc5c4)[C@@H](C)CN([C@@H](C)CO)C(=O)c3c2)cc1
BRD-K02251932,442141,BRD-K02251932,BRD-K02251932,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@H](CO)N1C[C@H](C)[C@H](CN(C)C(=O)NC2CCCCC2)Oc2c(NS(=O)(=O)c3ccc(F)cc3)cccc2C1=O
BRD-K02492147,415688,BRD-K02492147,BRD-K02492147,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,CN1CCN(CC1)C(=O)C[C@@H]1O[C@H](CO)[C@@H](NS(=O)(=O)c2cccc(F)c2)C=C1
BRD-K03536150,686134,BRD-K03536150,BRD-K03536150,270.0,probe,outreach,BAX,activator of BAX,Dana Farber Cancer Institute;Dana Farber Cancer Institute,DFCI-LW14,CC1=NN(C(=O)C\1=N\Nc1ccccc1C(O)=O)c1nc(cs1)-c1ccccc1
BRD-K03911514,660424,BRD-K03911514,BRD-K03911514,66.0,probe,outreach,,stapled helical peptide,Dana Farber Cancer Institute,,CCCC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@]1(C)CCC\C=C/CCC[C@](C)(NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(C)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
BRD-K04800985,435086,BRD-K04800985,BRD-K04800985,67.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@@H](CO)N1C[C@@H](C)[C@@H](CN(C)CC2CCCCC2)Oc2ccc(NC(=O)Nc3c(C)noc3C)cc2C1=O
BRD-K07442505,660229,BRD-K07442505,BRD-K07442505,66.0,probe,outreach,BAX,stapled helical peptide activating BAX,Dana Farber Cancer Institute;Dana Farber Cancer Institute,DFCI-LW13,CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1
BRD-K09344309,439882,BRD-K09344309,BRD-K09344309,33.0,probe,DOS;outreach,,screening hit,Broad Institute of MIT and Harvard,,C[C@H](CO)N1C[C@@H](C)[C@H](CN(C)Cc2ccc3OCOc3c2)Oc2c(NC(=O)c3ccncc3)cccc2C1=O
BRD-K09587429,416842,BRD-K09587429,BRD-K09587429,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@@H](NC(=O)C[C@@H]1CC[C@@H](NC(=O)CN2CCOCC2)[C@H](CO)O1)c1ccccc1
BRD-K11533227,389297,BRD-K11533227,BRD-K11533227,66.0,probe,chromatin;outreach,HDAC1;HDAC2,inhibitor of HDAC1 and HDAC2,Stanley Center for Psychiatric Research at the Broad Institute,,CC(=O)NC1CCN(CC1)C(=O)Nc1cc(ccc1N)-c1cccs1
BRD-K13185470,660839,BRD-K13185470,BRD-K13185470,66.0,probe,outreach,MCL1,stapled helical peptide targeting MCL1,Dana Farber Cancer Institute,,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@]1(C)CCC\C=C/CCC[C@](C)(NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
BRD-K13999467,410270,BRD-K13999467,BRD-K13999467,67.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@@H](CO)N1C[C@H](C)[C@H](CN(C)C(=O)Cc2ccncc2)Oc2cc(ccc2S1(=O)=O)C#Cc1ccccc1F
BRD-K14844214,402775,BRD-K14844214,BRD-K14844214,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,CC(C)CC#Cc1ccc2c(O[C@@H](CN(C)C(=O)c3cnccn3)[C@H](C)CN([C@H](C)CO)S2(=O)=O)c1
BRD-K16130065,660425,BRD-K16130065,BRD-K16130065,66.0,probe,outreach,,stapled helical peptide,Dana Farber Cancer Institute,,CC[C@H](C)[C@H](NC(C)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@]1(C)CCC\C=C/CCC[C@](C)(NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O
BRD-K16147474,447732,BRD-K16147474,BRD-K16147474,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,CC(C)NC(=O)Nc1ccc2O[C@@H](CN(C)S(C)(=O)=O)[C@@H](C)CN([C@H](C)CO)C(=O)Cc2c1
BRD-K17060750,600054,BRD-K17060750,BRD-K17060750,67.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,CN(C)CC(=O)N[C@@H]1CC[C@@H](CCNC(=O)Nc2ccc(F)cc2)O[C@H]1CO
BRD-K19103580,436211,BRD-K19103580,BRD-K19103580,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@H](CO)N1C[C@H](C)[C@H](CN(C)Cc2ccc(Cl)c(Cl)c2)Oc2ccc(cc2C1=O)N(C)C
BRD-K20514654,651304,BRD-K20514654,BRD-K20514654,66.0,probe,outreach,,stapled helical peptide,Harvard University,,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCNC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@]1(C)CCC\C=C/CCC[C@@](C)(NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O
BRD-K24690302,641721,BRD-K24690302,BRD-K24690302,66.0,probe,chromatin;outreach,HDAC1,inhibitor of HDAC1,Stanley Center for Psychiatric Research at the Broad Institute,,CN(C)CC1CN(C1)C(=O)Nc1cc(ccc1N)-c1ccc(F)cc1
BRD-K26531177,42319,BRD-K26531177,BRD-K26531177,330.0,probe,outreach,,analog of the natural product piperlongumine,Broad Institute of MIT and Harvard,,COc1cc(CCC(=O)N2CCC=CC2=O)cc(OC)c1OC
BRD-K27188169,660798,BRD-K27188169,BRD-K27188169,66.0,probe,outreach,,stapled helical peptide,Dana Farber Cancer Institute,,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@]1(C)CCC\C=C/CCC[C@](C)(NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
BRD-K27188169:NAVITOCLAX (2:1 MOL/MOL),665818,BRD-K27188169:NAVITOCLAX (2:1 MOL/MOL),BRD-M23096439,50.0,probe,combination,BCL2;BCL2L1;BCL2L2,"stapled helical peptide;inhibitor of BCL2, BCL-xL, and BCL-W",,,CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1.CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@]1(C)CCC\C=C/CCC[C@](C)(NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
BRD-K27224038,397964,BRD-K27224038,BRD-K27224038,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@@H](CO)N1C[C@H](C)[C@@H](CN(C)C(=O)C2CCOCC2)Oc2ncc(cc2C1=O)C#CC1(O)CCCC1
BRD-K27986637,452570,BRD-K27986637,BRD-K27986637,66.0,probe,DOS;outreach,,product of diversity oriented synthesis; screening hit,Broad Institute of MIT and Harvard,,C[C@H](CO)N1C[C@H](C)[C@H](CN(C)Cc2ccc3OCCOc3c2)OCc2cn(CCCC1=O)nn2
BRD-K28456706,651642,BRD-K28456706,BRD-K28456706,66.0,probe,chromatin;lit-search;synthesis,HNF4A,inhibitor of hepatocyte nuclear factor 4 alpha,Broad Institute of MIT and Harvard,,Cc1c(oc2ccc3ccccc3c12)[N+]([O-])=O
BRD-K29086754,448891,BRD-K29086754,BRD-K29086754,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@H](CO)N1C[C@@H](C)[C@@H](CN(C)Cc2ccc(cc2)C(O)=O)Oc2ccc(NC(=O)Nc3ccc(F)cc3)cc2CC1=O
BRD-K29313308,634814,BRD-K29313308,BRD-K29313308,66.0,probe,chromatin;outreach,HDAC3,inhibitor of HDAC3,Stanley Center for Psychiatric Research at the Broad Institute,,CC(=O)Nc1ccc(cc1)C(=O)Nc1ccc(F)cc1N
BRD-K30019337,437263,BRD-K30019337,BRD-K30019337,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,CC(C)NC(=O)N(C)C[C@H]1Oc2ccc(cc2C(=O)N(C[C@H]1C)[C@H](C)CO)N(C)C
BRD-K30748066,689506,BRD-K30748066,BRD-K30748066,66.0,probe,kinome,CDK9,inhibitor of CDK9,Broad Institute of MIT and Harvard,,Cc1c(sc(=O)n1C)-c1ccnc(Nc2ccc(cc2)N2CCNCC2)n1
BRD-K33199242,449707,BRD-K33199242,BRD-K33199242,67.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,CNC[C@@H]1Oc2ccc(cc2CC(=O)N(C[C@@H]1C)[C@@H](C)CO)N(C)C
BRD-K33514849,401251,BRD-K33514849,BRD-K33514849,34.0,probe,outreach,,screening hit,Broad Institute of MIT and Harvard,,C[C@H](CO)N1C[C@@H](C)[C@H](CN(C)C(=O)Nc2ccc3OCOc3c2)Oc2cc(ccc2S1(=O)=O)C#Cc1ccncc1
BRD-K34099515,660064,BRD-K34099515,BRD-K34099515,66.0,probe,DOS;outreach,,screening hit,Broad Institute of MIT and Harvard,,CC(C)N1C[C@@H](C)[C@H](CN(C)Cc2ccc(Oc3ccccc3)cc2)Oc2c(NC(=O)c3ccncc3)cccc2C1=O
BRD-K34222889,688888,BRD-K34222889,BRD-K34222889,66.0,probe,outreach,,analog of the natural product piperlongumine,Broad Institute of MIT and Harvard,,COc1ccc(cc1)C#CC1=CCCN(C(=O)\C=C\c2cc(OC)c(OC)c(OC)c2)C1=O
BRD-K34485477,446716,BRD-K34485477,BRD-K34485477,33.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,CNC[C@@H]1Oc2ccc(NC(=O)CCN3CCOCC3)cc2CC(=O)N(C[C@@H]1C)[C@H](C)CO
BRD-K35604418,660230,BRD-K35604418,BRD-K35604418,270.0,probe,outreach,MCL1,inhibitor of MCL1,Dana Farber Cancer Institute,,Cc1cs\c(=N/C2CCCCC2)n1\N=C\c1ccc(O)c(O)c1O
BRD-K37390332,463198,BRD-K37390332,BRD-K37390332,33.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@H](CO)N1C[C@H](C)[C@@H](CN(C)C(=O)Nc2cccc3ccccc23)Oc2ccc(NC(=O)c3ccncc3)cc2CC1=O
BRD-K41334119,446546,BRD-K41334119,BRD-K41334119,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,CNC[C@@H]1Oc2ccc(NS(C)(=O)=O)cc2CC(=O)N(C[C@@H]1C)[C@H](C)CO
BRD-K41597374,404452,BRD-K41597374,BRD-K41597374,67.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@H](CO)N1C[C@H](C)[C@H](CN(C)C(=O)Nc2cc(F)ccc2F)Oc2cc(ccc2S1(=O)=O)C#CC1CCCC1
BRD-K42260513,687715,BRD-K42260513,BRD-K42260513,66.0,probe,chromatin;lit-search;synthesis,EZH2,inhibitor of enhancer of zeste polycomb repressive complex 2 subunit,Broad Institute of MIT and Harvard,,CC(C)n1ncc2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O
BRD-K44224150,438564,BRD-K44224150,BRD-K44224150,34.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,CNC[C@@H]1Oc2ccc(NC(=O)C3CCCCC3)cc2C(=O)N(C[C@@H]1C)[C@@H](C)CO
BRD-K45681478,142931,BRD-K45681478,BRD-K45681478,66.0,probe,DOS;outreach,,product of diversity oriented synthesis; screening hit,Broad Institute of MIT and Harvard,,ClC1=C(NCC=C)C(=O)c2ccccc2C1=O
BRD-K48334597,431987,BRD-K48334597,BRD-K48334597,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@H](CO)N1C[C@H](C)[C@@H](CN(C)C(=O)NC2CCCCC2)Oc2ccc(NC(=O)Cc3cn(C)c4ccccc34)cc2C1=O
BRD-K48477130,649754,BRD-K48477130,BRD-K48477130,66.0,probe,lit-search;synthesis,,screening hit,Stanley Center for Psychiatric Research at the Broad Institute,,Cc1n[nH]c2NC3=C([C@@H](c12)c1ccccc1)C(=O)CC(C)(C)C3
BRD-K49290616,414479,BRD-K49290616,BRD-K49290616,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,OC[C@@H]1O[C@@H](CC(=O)NCc2ccncn2)CC[C@H]1NC(=O)c1ccc(F)cc1
BRD-K50799972,596868,BRD-K50799972,BRD-K50799972,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,COc1ccccc1-c1cccc(c1)-c1nc(cc2CN([C@@H](CCO)c12)[S@@](=O)C(C)(C)C)C(=O)NCc1ccncc1
BRD-K51490254,616355,BRD-K51490254,BRD-K51490254,66.0,probe,chromatin;outreach,HDAC6;HDAC8,inhibitor of HDAC6 and HDAC8,Stanley Center for Psychiatric Research at the Broad Institute,,ONC(=O)c1cccc(c1)C(=O)Nc1ccccc1
BRD-K51831558,687661,BRD-K51831558,BRD-K51831558,66.0,probe,chromatin;lit-search;synthesis,EZH2,inhibitor of enhancer of zeste polycomb repressive complex 2 subunit,Broad Institute of MIT and Harvard,,CC(C)n1ncc2c(cc(Br)cc12)C(=O)NCc1c(C)cc(C)[nH]c1=O
BRD-K52037352,450415,BRD-K52037352,BRD-K52037352,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@@H](CO)N1C[C@H](C)[C@H](CN(C)C(=O)Nc2cccc3ccccc23)Oc2ccc(NC(=O)NC3CCCCC3)cc2CC1=O
BRD-K55116708,444779,BRD-K55116708,BRD-K55116708,66.0,probe,DOS;outreach,,product of diversity oriented synthesis; inhibitor of leukemic stem cells,Broad Institute of MIT and Harvard,,C[C@@H](CO)N1C[C@@H](C)[C@@H](CN(C)Cc2ccc(cc2)C(=O)Nc2ccccc2N)Oc2c(NC(=O)Nc3ccccc3)cccc2C1=O
BRD-K55473186,651306,BRD-K55473186,BRD-K57252013,66.0,probe,outreach,NOTCH1,stapled helical peptide targeting NOTCH1,Harvard University,,CCC(C)C(NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)O)NC(=O)CCNC(=O)C)C(=O)NC1(C)CCCC=CCCCC(C)(NC(=O)C(CCCNC(=N)N)NC(=O)C(CS)NC(=O)C(CC(C)C)NC1=O)C(=O)NC(Cc2c[nH]cn2)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N
BRD-K58730230,660797,BRD-K58730230,BRD-K58730230,66.0,probe,outreach,,stapled helical peptide,Dana Farber Cancer Institute,,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@]1(C)CCC\C=C/CCC[C@](C)(NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
BRD-K61166597,348633,BRD-K61166597,BRD-K61166597,66.0,probe,chromatin;outreach,,inhibitor of HDAC1 and HDAC2,Stanley Center for Psychiatric Research at the Broad Institute,,Nc1ccc(cc1NC(=O)c1ccc(cc1)C(=O)NCCc1ccncc1)-c1cccs1
BRD-K63431240,404566,BRD-K63431240,BRD-K63431240,66.0,probe,DOS;outreach,,product of diversity oriented synthesis; screening hit,Broad Institute of MIT and Harvard,,C[C@@H](CO)N1C[C@H](C)[C@@H](CN(C)C(=O)Nc2ccc3OCOc3c2)Oc2cc(ccc2S1(=O)=O)C#Cc1ccncc1
BRD-K64610608,438776,BRD-K64610608,BRD-K64610608,33.0,probe,DOS;outreach,,product of diversity oriented synthesis; screening hit,Broad Institute of MIT and Harvard,,COc1ccc(cc1)S(=O)(=O)N(C)C[C@@H]1Oc2c(NC(=O)Nc3cccc4ccccc34)cccc2C(=O)N(C[C@H]1C)[C@@H](C)CO
BRD-K66453893,387472,BRD-K66453893,BRD-K66453893,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@@H](CO)N1C[C@H](C)[C@H](CN(C)S(=O)(=O)c2ccc(Cl)cc2)Oc2ccc(NC(=O)CCC(F)(F)F)cc2CC1=O
BRD-K66532283,376693,BRD-K66532283,BRD-K66532283,66.0,probe,chromatin;outreach,HDAC1;HDAC2,inhibitor of HDAC1 and HDAC2,Stanley Center for Psychiatric Research at the Broad Institute,,Nc1ccc(cc1NC(=O)C1=CCCC1)-c1cccs1
BRD-K70511574,648987,BRD-K70511574,BRD-K62825658,66.0,probe,kinome,PLK1,inhibitor of polo-like kinase 1 (PLK1),Selleck,S1485,COc1ccc(cc1)S(=O)(=O)N(C(=O)C)c2ccccc2C=Cc3cc[n+]([O-])cc3
BRD-K71781559,425733,BRD-K71781559,BRD-K71781559,66.0,probe,outreach,,screening hit,National Cancer Institute Chemotherapeutic Agents Repository,,OC(=O)c1ccc(NCc2nc3cc4ccccc4cc3[nH]2)cc1
BRD-K71935468,58566,BRD-K71935468,BRD-K71935468,83.0,probe,DOS;outreach,,inducer of ROS,Broad Institute of MIT and Harvard,,COC(=O)C(CC#Cc1ccc2NC(=O)[C@@]3([C@H]([C@H]4N([C@H]3c3ccccc3OCCO)[C@@H]([C@@H](OC4=O)c3ccccc3)c3ccccc3)C(=O)N3CCN(CC3)c3ncccn3)c2c1)C(=O)OC
BRD-K75293299,438691,BRD-K75293299,BRD-K75293299,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@@H](CO)N1C[C@@H](C)[C@H](CN(C)C(=O)Nc2cccc3ccccc23)Oc2c(NC(=O)c3ccncc3)cccc2C1=O
BRD-K78574327,435898,BRD-K78574327,BRD-K78574327,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@H](CO)N1C[C@H](C)[C@H](CN(C)CC2CC2)Oc2ccc(NS(=O)(=O)c3cn(C)cn3)cc2C1=O
BRD-K79669418,660139,BRD-K79669418,BRD-K79669418,66.0,probe,outreach,MDM2;MDM4,inhibitor of MDM4-p53 interaction,Dana Farber Cancer Institute,,CC(C)C[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@](C)(CCCCCC\C=C/CCC[C@](C)(NC(=O)[C@H](CC(C)C)NC1=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(C)=O)[C@@H](C)O
BRD-K80183349,376307,BRD-K80183349,BRD-K80183349,66.0,probe,chromatin;outreach,HDAC1;HDAC2,inhibitor of HDAC1 and HDAC2,Stanley Center for Psychiatric Research at the Broad Institute,,CC(=O)N1CCC(CC1)C(=O)Nc1cc(ccc1N)-c1cccs1
BRD-K84807411,437906,BRD-K84807411,BRD-K84807411,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C[C@H](CO)N1C[C@H](C)[C@@H](CN(C)C)Oc2c(NC(=O)c3cc(C)nn3C)cccc2C1=O
BRD-K85133207,616408,BRD-K85133207,BRD-K85133207,66.0,probe,chromatin;outreach,HDAC1,inhibitor of HDAC1,Stanley Center for Psychiatric Research at the Broad Institute,,CC(=O)N[C@H]1C[C@H](C1)C(=O)Nc1cc(ccc1N)-c1ccc(F)cc1
BRD-K86535717,429535,BRD-K86535717,BRD-K86535717,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,CO[C@@H]1CC[C@H]2CCN(C)C(=O)[C@@H](C)[C@H](CN(C)C(=O)c3cccc(C#N)c3OC[C@H]1O2)OC
BRD-K88742110,606670,BRD-K88742110,BRD-K88742110,66.0,probe,chromatin;outreach,HDAC8,inhibitor of HDAC8,Stanley Center for Psychiatric Research at the Broad Institute,,COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1
BRD-K90370028,362207,BRD-K90370028,BRD-K90370028,33.0,probe,outreach,,screening hit,Broad Institute of MIT and Harvard,,CC(=O)N[C@@H]1C\C=C\CCC(=O)N[C@@H](COC1=O)c1ccccc1
BRD-K92856060,119769,BRD-K92856060,BRD-K92856060,33.0,probe,DOS;outreach,,screening hit,ChemBridge Corporation,7653590,COc1ccc(cc1[N+]([O-])=O)S(=O)(=O)N(C(C)=O)c1ccc(OC(C)=O)c2ccccc12
BRD-K94991378,53556,BRD-K94991378,BRD-K94991378,83.0,probe,DOS;outreach,,inducer of ROS,Broad Institute of MIT and Harvard,,COCCOC(=O)N1C(=O)[C@]2([C@@H]([C@@H]3N([C@@H]2c2ccccc2OCCO)[C@H]([C@H](OC3=O)c2ccccc2)c2ccccc2)C(=O)NCC=C)c2cc(ccc12)C#CCC(C(=O)OC)C(=O)OC
BRD-K96431673,417262,BRD-K96431673,BRD-K96431673,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,CN1CCN(CC1)C(=O)C[C@H]1CC[C@H](NC(=O)c2ccc3OCOc3c2)[C@@H](CO)O1
BRD-K96970199,410703,BRD-K96970199,BRD-K96970199,66.0,GE-active,DOS;profiling,,product of diversity oriented synthesis,Broad Institute of MIT and Harvard,,C\C=C\c1ccc2c(O[C@@H](CN(C)C(=O)c3ccccc3)[C@@H](C)CN([C@@H](C)CO)S2(=O)=O)c1
BRD-K97651142,660135,BRD-K97651142,BRD-K97651142,66.0,probe,outreach,,aphrocallistin derivative,Sanford-Burnham Medical Research Institute,,CN(CCc1cc(Br)c(OCCCNc2ncnc3n(C)cnc23)c(Br)c1)C(=O)c1ccc(C)cc1
BRD-K99006945,687395,BRD-K99006945,BRD-K99006945,66.0,probe,chromatin;lit-search;synthesis,,screening hit,Broad Institute of MIT and Harvard,,CCN(CC)c1ccc(cc1)C1=NNC(=O)C[C@H]1C
BRD-K99584050,660140,BRD-K99584050,BRD-K99584050,66.0,probe,outreach,,stapled helical peptide,Dana Farber Cancer Institute,,CC[C@H](C)[C@H](NC(C)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@]1(C)CCC\C=C/CCC[C@](C)(NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O
BRD-M00053801,660890,BRD-M00053801,BRD-M00053801,66.0,probe,lit-search;synthesis,BCL2,inhibitor of BCL2,Broad Institute of MIT and Harvard,,C[C@H](O)[C@@H]1[C@H](CO)ON(Cc2cccc(CN(CCN(C)C)[C@H](C3CCCCC3)c3ccccc3)c2)[C@@H]1C(=O)N[C@H]1C[C@H]2C[C@@H]([C@@H]1C)C2(C)C.C[C@H](O)[C@@H]1[C@H](CO)ON(Cc2cccc(CN(CCN(C)C)[C@@H](C3CCCCC3)c3ccccc3)c2)[C@@H]1C(=O)N[C@H]1C[C@H]2C[C@@H]([C@@H]1C)C2(C)C
BRD1812,418162,BRD1812,BRD-K73261812,66.0,probe,pilot-set,,screening hit,ChemPacific,46704,Oc1ccc(C[C@@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1
BRD1835,404070,BRD1835,BRD-K62801835,130.0,probe,chromatin;DOS;outreach,EZH2,product of diversity oriented synthesis; screening hit,Broad Institute of MIT and Harvard,,C[C@@H](CO)N1C[C@H](C)[C@@H](CN(C)Cc2ccc(cc2)C(O)=O)Oc2cc(ccc2S1(=O)=O)C#CCC1CCCC1
BRD4132,3588,BRD4132,BRD-K86574132,160.0,probe,chromatin;pilot-set,,screening hit,ChemDiv Inc.,4998-1380,CC(C)N1C(=O)S\C(=C\c2ccc(Sc3nc4ccccc4[nH]3)o2)C1=O
BRD6340,12877,BRD6340,BRD-K35716340,33.0,probe,chromatin;pilot-set,,screening hit,ChemDiv Inc.,1988-0090,C(Cn1c2ccccc2c2ccccc12)c1nc2ccccc2[nH]1
BRD8899,608062,BRD8899,BRD-K22828899,33.0,probe,lit-search;synthesis,STK33,inhibitor of serine/threonine kinasase STK33,Broad Institute of MIT and Harvard,,CC(=O)NC[C@@H]1C[C@H](CN1)NS(=O)(=O)c1cccc2cncc(C)c12
BRD8958,418163,BRD8958,BRD-K68548958,66.0,probe,chromatin;pilot-set,EP300,inhibitor of E1A binding protein p300,Princeton BioMolecular Research,OSSK_701387,CC1=NN(C(=O)C\1=C\c1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O
BRD9647,37479,BRD9647,BRD-K05649647,33.0,probe,pilot-set,,screening hit,ChemBridge Corporation,7910659,COc1ccc(cc1)N(C(=O)c1ccccc1)S(=O)(=O)c1cc(OC)ccc1OC
BRD9876,19153,BRD9876,BRD-K89329876,130.0,probe,pilot-set,,screening hit,Sigma-Aldrich,425265,CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N
BRD9876:MK-1775 (4:1 MOL/MOL),689136,BRD9876:MK-1775 (4:1 MOL/MOL),BRD-M80099012,66.0,probe,combination,WEE1,screening hit;inhibitor of WEE1,,,CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N.CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1
BREFELDIN A,411714,BREFELDIN A,BRD-A31107743,37.0,probe,pilot-set,ARF1,modulator of ADP-ribosylation factor 1; inhibitor of protein translocation from ER to Golgi,ChemBridge Corporation,6908419,CC1CCC\C=C/C2CC(O)CC2C(O)\C=C/C(=O)O1
BRIVANIB,606246,BRIVANIB,BRD-K28428262,66.0,clinical,lit-search,FLT1;KDR,inhibitor of VEGFR 1/2,Selleck,S1084,C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C
BYL-719,668495,BYL-719,BRD-K54997624,66.0,clinical,kinome,PIK3CA,inhibitor of PI3K catalytic subunit alpha,Active Biochem,A-1214,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F
C6-CERAMIDE,44554,C6-CERAMIDE,BRD-K08608874,66.0,probe,lit-search,MAPK1;PPP2CA;UGCG,inhibitor of glucosylceramide synthase; activator of MAP kinase (ERK); stimulator of protein phosphatase 2A,Sigma-Aldrich,H6524,CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(=O)CCCCC
CABOZANTINIB,660840,CABOZANTINIB,BRD-K51544265,66.0,FDA,CTEP;kinome,FLT3;KDR;MET;RET,"inhibitor of c-MET, VEGFR2/3, and RET",Selleck,S1119,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC
CAL-101,660430,CAL-101,BRD-K60866521,66.0,clinical,kinome,PIK3CD,inhibitor of PI3K catalytic subunit delta,Selleck,S2226,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1
CANERTINIB,606138,CANERTINIB,BRD-K50168500,66.0,clinical,kinome,EGFR;ERBB2,inhibitor of EGFR and HER2,Selleck,S1019,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl
CARBOPLATIN,26979,CARBOPLATIN,BRD-K11626735,66.0,FDA,std-of-care,,inducer of DNA damage,Selleck,S1215,O=C1O[Pt]OC(=O)C11CCC1
CARBOPLATIN:ETOPOSIDE (40:17 MOL/MOL),660223,CARBOPLATIN:ETOPOSIDE (40:17 MOL/MOL),BRD-M63575423,48.0,probe,combination,TOP2A,inducer of DNA damage;inhibitor of topoisomerase II,,,O=C1O[Pt]OC(=O)C11CCC1.COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12
CARBOPLATIN:UNC0638 (2:1 MOL/MOL),660130,CARBOPLATIN:UNC0638 (2:1 MOL/MOL),BRD-M18136176,50.0,probe,combination,EHMT1;EHMT2,inducer of DNA damage;inhibitor of EHMT2 and GLP methyltransferase,,,O=C1O[Pt]OC(=O)C11CCC1.COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1
CAY10576,622913,CAY10576,BRD-K51781482,66.0,probe,kinome;outreach,IKBKE,inhibitor of IKK-epsilon,Calbiochem,401488,COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(s3)C#N)c2cc1OC
CAY10594,411824,CAY10594,BRD-K61662457,66.0,probe,pilot-set,PLD2,inhibitor of phospholipase D2,Cayman,13207,O=C(NCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc2ccccc2c1
CAY10618,632104,CAY10618,BRD-K83289131,33.0,probe,pilot-set,NAMPT,inhibitor of nicotinamide phosphoribosyltransferase,Cayman,13670,O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1
CBB-1007,687721,CBB-1007,BRD-K84754008,66.0,probe,lit-search,KDM1A,inhibitor of lysine-specific demethylase 1A (LSD1),Broad Institute of MIT and Harvard,,COC(=O)c1cc(CN2CCN(CC2)C(N)=N)cc(c1)C(=O)N1CCN(CC1)C(=O)c1ccc(cc1)C(N)=N
CCT036477,417663,CCT036477,BRD-A22997170,33.0,probe,pilot-set,,inhibitor of WNT signaling by blocking beta-catenin transcription,Sigma-Aldrich,SML0151,Cc1[nH]c2ccccc2c1C(Nc1ccccn1)c1ccc(Cl)cc1
CD-1530,375562,CD-1530,BRD-K25737009,130.0,probe,chromatin;pilot-set,RARG,agonist of retinoic acid receptor gamma,Tocris Bioscience,2554,OC(=O)c1ccc(cc1)-c1ccc2cc(c(O)cc2c1)C12CC3CC(CC(C3)C1)C2
CD-437,375256,CD-437,BRD-K28907958,37.0,probe,chromatin;pilot-set,RARG,agonist of retinoic acid receptor gamma,Sigma-Aldrich,C5865,OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2
CEDIRANIB,606136,CEDIRANIB,BRD-K86930074,66.0,clinical,CTEP;kinome,FLT1;FLT4;KDR,inhibitor of VEGFRs,Selleck,S1017,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
CERANIB-2,660078,CERANIB-2,BRD-K31514534,66.0,probe,lit-search,ACER1;ACER2;ACER3;ASAH1;ASAH2;ASAH2B,inhibitor of ceramidase activity,Cayman,11092,COc1ccc(\C=C\C(=O)c2c(-c3ccccc3)c3ccccc3[nH]c2=O)cc1
CERULENIN,52430,CERULENIN,BRD-K52075040,150.0,probe,pilot-set,FASN;HMGCS1,inhibitor of fatty acid synthase; inhibitor of HMG-CoA synthase,Cayman,10005647,C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O
CH-55,660137,CH-55,BRD-K71487808,66.0,probe,chromatin;lit-search,RARA;RARB;RARG,agonist of retinoid acid receptors,Axon Medchem,1241,CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O
CHIR-99021,347812,CHIR-99021,BRD-K16189898,80.0,probe,kinome;pilot-set,GSK3B,inhibitor of GSK3 beta,Selleck,S1263,Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl
CHLORAMBUCIL,25334,CHLORAMBUCIL,BRD-K29458283,270.0,FDA,std-of-care,,DNA alkylator,Sigma-Aldrich,C0253,OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl
CHM-1,609674,CHM-1,BRD-K94145482,16.0,probe,pilot-set,,inhibitor of tubulin polymerization,Tocris Bioscience,3868,Fc1ccccc1-c1cc(=O)c2cc3OCOc3cc2[nH]1
CI-976,375390,CI-976,BRD-K88544581,270.0,probe,pilot-set,ACAT1,inhibitor of acetyl-CoA acetyltransferase I,Sigma-Aldrich,C3743,CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC
CICLOPIROX,28784,CICLOPIROX,BRD-K13044802,66.0,FDA,lit-search,RRM1,substituted pyridone antimycotic; inhibitor of the iron-dependent enzyme ribonucleotide reductase,Sigma-Aldrich,C0415,Cc1cc(C2CCCCC2)n(O)c(=O)c1
CICLOSPORIN,55512,CICLOSPORIN,BRD-A38030642,33.0,FDA,pilot-set,PPID,inhibitor of calcineurin by binding to cyclophilin D,Tocris Bioscience,1101,CCC1NC(=O)C([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
CID-5951923,267119,CID-5951923,BRD-A86956638,66.0,probe,chromatin;lit-search,KLF5,modulator of KLF5 expression,Tocris Bioscience,4446,CN(C1CCS(=O)(=O)C1)C(=O)COC(=O)\C=C\c1cccc(c1)[N+]([O-])=O
CIL41,176181,CIL41,BRD-K05392795,160.0,probe,pilot-set,,screening hit,Columbia University,,N=C(NOC(=O)C12CC3CC(CC(C3)C1)C2)c1ccccc1
CIL55,1788,CIL55,BRD-K46556387,10.0,probe,pilot-set,,screening hit,Columbia University,,CN(C)CCNC(=O)c1cc2CSc3cc(Cl)ccc3-c2s1
CIL55A,609061,CIL55A,BRD-K69982010,80.0,probe,pilot-set,,screening hit,Columbia University,,CN(C)CCNC(=O)c1cc2CSc3ccc(Cl)cc3-c2s1
CIL56,100490,CIL56,BRD-K11740178,2.5,probe,pilot-set,,screening hit,Columbia University,,ON=C1c2cc(ccc2-c2ccc(cc12)S(=O)(=O)N1CCCCC1)S(=O)(=O)N1CCCCC1
CIL70,183526,CIL70,BRD-K20215950,40.0,probe,pilot-set,,screening hit,Columbia University,,Clc1ccc(CC(=N)NOC(=O)c2cccc3ccccc23)cc1
CIMETIDINE,26870,CIMETIDINE,BRD-K34157611,270.0,FDA,lit-search,HRH2,inhibitor of histidine receptor H2,Tocris Bioscience,0902,CN\C(NCCSCc1nc[nH]c1C)=N/C#N
CLOFARABINE,660288,CLOFARABINE,BRD-K34022604,66.0,FDA,std-of-care,,inducer of DNA damage,Selleck,S1218,Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
COL-3,665914,COL-3,BRD-A59431241,66.0,clinical,outreach,,analog of tetracycline,Harvard University,,NC(=O)C1C(=O)C[C@@H]2C[C@@H]3Cc4cccc(O)c4C(=O)C3C(=O)[C@]2(O)C1=O
COMPOUND 1541A,411827,COMPOUND 1541A,BRD-K30064966,37.0,probe,pilot-set,CASP3;CASP6;CASP7,"activators of executioner procaspases 3, 6, and 7",WuXi AppTec,TH02435-020-1,Oc1cccc2cc(C(=O)Nc3cccc(c3)-c3cn4ccccc4n3)c(=O)oc12
COMPOUND 1B,62111,COMPOUND 1B,BRD-A42556028,66.0,probe,chromatin;outreach,,screening hit,Enamine Ltd.,T0503-7331,CCN(CC)c1ccc(cc1[N+]([O-])=O)C1=NNC(=O)CC1C
COMPOUND 23 CITRATE,417451,COMPOUND 23 CITRATE,BRD-K67112618,33.0,probe,pilot-set,,analog of natural product cortistatin,Harvard University,,CN(C)[C@H]1CC[C@H]2[C@@H](CC[C@H]3[C@@H]4CC=C(c5ccc6cnccc6c5)[C@@]4(C)CC[C@H]23)C1
COMPOUND 7D-CIS,411805,COMPOUND 7D-CIS,BRD-K61829047,33.0,probe,pilot-set,XPO1,inhibitor of CRM1-mediated nucleocytoplasmic transport,WuXi AppTec,TH02330-015-1,CCOC(=O)\C=C/n1nnc(n1)-c1cccc(Cl)c1
CR-1-31B,418209,CR-1-31B,BRD-K23547378,33.0,probe,pilot-set,EIF4A2;EIF4E;EIF4G1,silvestrol analog; inhibits translation by modulating the eIF4F complex,Boston University,,CONC(=O)[C@H]1[C@@H](O)[C@@]2(O)c3c(O[C@]2([C@@H]1c1ccccc1)c1ccc(OC)cc1)cc(OC)cc3OC
CRIZOTINIB,628603,CRIZOTINIB,BRD-K78431006,66.0,FDA,kinome;std-of-care,ALK;MET,inhibitor of c-MET and ALK,Selleck,S1068,C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl
CRIZOTINIB:PLX-4032 (2:1 MOL/MOL),660857,CRIZOTINIB:PLX-4032 (2:1 MOL/MOL),BRD-M95284333,50.0,probe,combination,ALK;MET;BRAF,inhibitor of c-MET and ALK;inhibitor of BRAF,,,C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl.CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F
CUCURBITACIN I,595102,CUCURBITACIN I,BRD-A28105619,33.0,probe,chromatin;outreach,,natural product; modulator of NFKB1 and STAT3 signaling,Tocris Bioscience,1571,CC(C)(O)\C=C\C(=O)[C@](C)(O)C1[C@H](O)C[C@@]2(C)C3CC=C4C(CC(=O)C(=O)C4(C)C)[C@]3(C)C(=O)C[C@]12C
CURCUMIN,28452,CURCUMIN,BRD-K74148702,170.0,clinical,pilot-set,,natural product; modulator of ROS; modulator of NF-kappa-B signaling,Cayman,81025,COc1cc(C=CC(=O)CC(=O)C=Cc2ccc(O)c(OC)c2)ccc1O
CYANOQUINOLINE 11,417415,CYANOQUINOLINE 11,BRD-K00088062,130.0,clinical,kinome;pilot-set,MAP3K8,inhibitor of MAP3K8; inhibitor of phosphorylated EGFR in cells,WuXi AppTec,TH02434-056,Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cnc[nH]4)cc23)C#N)cc1Cl
CYCLOPHOSPHAMIDE,32620,CYCLOPHOSPHAMIDE,BRD-A09722536,130.0,FDA,std-of-care,,DNA alkylator,Sigma-Aldrich,C0768,ClCCN(CCCl)P1(=O)NCCCO1
CYTARABINE HYDROCHLORIDE,62690,CYTARABINE HYDROCHLORIDE,BRD-K33106058,66.0,FDA,std-of-care,,inducer of DNA damage,Selleck,S1648,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
CYTOCHALASIN B,50163,CYTOCHALASIN B,BRD-K26664453,33.0,probe,pilot-set,,inhibitor of actin polymerization,Sigma-Aldrich,C6762,C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C\[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C
DABRAFENIB,687954,DABRAFENIB,BRD-K09951645,66.0,clinical,CTEP;kinome,BRAF,inhibitor of BRAF,Active Biochem,A-1219,CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F
DACARBAZINE,32622,DACARBAZINE,BRD-K35520305,66.0,FDA,std-of-care,,DNA alkylator,Selleck,S1221,CN(C)\N=N\c1[nH]cnc1C(N)=O
DAPORINAD,418166,DAPORINAD,BRD-K58550667,2.0,clinical,pilot-set,NAMPT,inhibitor of nicotinamide phosphoribosyltransferase,Axon Medchem;Cayman,1279;13287,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1
DARINAPARSIN,609121,DARINAPARSIN,BRD-K35723520,33.0,clinical,pilot-set,,inducer of ROS; inhibitor of microtubule assembly,Sigma-Aldrich,D2071,C[As](C)SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O
DASATINIB,52882,DASATINIB,BRD-K49328571,66.0,FDA,CTEP;kinome;std-of-care,EPHA2;KIT;LCK;SRC;YES1,"inhibitor of SRC, YES1, EPHA2, c-KIT, and LCK",Selleck,S1021,Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1
DBEQ,199337,DBEQ,BRD-K59204667,66.0,probe,lit-search,VCP,inhibitor of p97 in cells,Tocris Bioscience,4417,C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1
DECITABINE,347775,DECITABINE,BRD-K79254416,66.0,FDA,chromatin;CTEP;std-of-care,DNMT1,inhibitor of DNA methyltransferase,Selleck,S1200,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
DECITABINE:CARBOPLATIN (1:1 MOL/MOL),660250,DECITABINE:CARBOPLATIN (1:1 MOL/MOL),BRD-M60251345,66.0,probe,combination,DNMT1,inhibitor of DNA methyltransferase;inducer of DNA damage,,,O=C1O[Pt]OC(=O)C11CCC1.Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
DECITABINE:NAVITOCLAX (2:1 MOL/MOL),660180,DECITABINE:NAVITOCLAX (2:1 MOL/MOL),BRD-M43399311,50.0,probe,combination,DNMT1;BCL2;BCL2L1;BCL2L2,"inhibitor of DNA methyltransferase;inhibitor of BCL2, BCL-xL, and BCL-W",,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
DEXAMETHASONE,277354,DEXAMETHASONE,BRD-A35108200,33.0,FDA,pilot-set,NR3C1,agonist of glucocorticoid receptor,ChemDiv Inc.,R092-0055,CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
DINACICLIB,687578,DINACICLIB,BRD-K13662825,66.0,clinical,chromatin;CTEP;kinome,CDK1;CDK2;CDK5;CDK9,inhibitor of cyclin-dependent kinases,Selleck,S2678,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO
DOCETAXEL,660364,DOCETAXEL,BRD-A05821830,66.0,FDA,std-of-care,,inhibitor of microtubule assembly,Selleck,S1148,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)C2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C
DOCETAXEL:TANESPIMYCIN (2:1 MOL/MOL),660217,DOCETAXEL:TANESPIMYCIN (2:1 MOL/MOL),BRD-M60574774,50.0,probe,combination,HSP90AA1,inhibitor of microtubule assembly;inhibitor of HSP90,,,CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O.CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)C2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C
DOXORUBICIN,36599,DOXORUBICIN,BRD-K92093830,66.0,FDA,std-of-care,TOP2A,inhibitor of topoisomerase II,Selleck,S1208,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO
DOXORUBICIN:NAVITOCLAX (2:1 MOL/MOL),660280,DOXORUBICIN:NAVITOCLAX (2:1 MOL/MOL),BRD-M01915239,50.0,probe,combination,TOP2A;BCL2;BCL2L1;BCL2L2,"inhibitor of topoisomerase II;inhibitor of BCL2, BCL-xL, and BCL-W",,,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
ELCPK,609056,ELCPK,BRD-K44847641,0.4,probe,pilot-set,,screening hit,ChemDiv Inc.,G408-2080,O=S(=O)(N1CCCc2ccccc12)c1ccc(cc1)-c1cnc(o1)C1CC1
ELOCALCITOL,660319,ELOCALCITOL,BRD-A04287157,66.0,clinical,lit-search,VDR,agonist of vitamin D receptor,Axon Medchem,1676,CCC(O)(CC)\C=C\CC(C)C1=CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](F)C1=C
ENTINOSTAT,60218,ENTINOSTAT,BRD-K77908580,66.0,clinical,chromatin;CTEP;outreach,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",Stanley Center for Psychiatric Research at the Broad Institute,,Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1
EPIGALLOCATECHIN-3-MONOGALLATE,28801,EPIGALLOCATECHIN-3-MONOGALLATE,BRD-K55591206,300.0,probe,pilot-set,,natural product,Selleck,S2250,Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1
ERASTIN,63578,ERASTIN,BRD-A25004090,66.0,probe,pilot-set,SLC7A11;VDAC1;VDAC2,modulator of voltage-dependent anion channels; inhibitor of solute carrier SLC7A11,Sigma-Aldrich,E7781,CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1
ERISMODEGIB,636425,ERISMODEGIB,BRD-K19796430,33.0,probe,chromatin;pilot-set,,screening hit,Selleck,S2151,C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1
ERLOTINIB,52928,ERLOTINIB,BRD-K70401845,66.0,FDA,CTEP;kinome;std-of-care,EGFR;ERBB2,inhibitor of EGFR and HER2,Selleck,S1023,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC
ERLOTINIB:PLX-4032 (2:1 MOL/MOL),660768,ERLOTINIB:PLX-4032 (2:1 MOL/MOL),BRD-M27152968,50.0,probe,combination,EGFR;ERBB2;BRAF,inhibitor of EGFR and HER2;inhibitor of BRAF,,,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC.CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F
ETOMOXIR,660082,ETOMOXIR,BRD-K81335284,300.0,clinical,pilot-set,CPT1A,inhibitor of carnitine palmitoyltransferase,Sigma-Aldrich,E1905,OC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1
ETOPOSIDE,48589,ETOPOSIDE,BRD-K37798499,28.0,FDA,pilot-set;std-of-care,TOP2A,inhibitor of topoisomerase II,Selleck,S1225,COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12
ETP-46464,666716,ETP-46464,BRD-K24556407,66.0,probe,lit-search,ATM;ATR,inhibitor of serine/threonine-protein kinase ATR,Spanish National Cancer Research Centre,,CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1
EX-527,608999,EX-527,BRD-K76964878,80.0,clinical,chromatin;pilot-set,SIRT1,inhibitor of sirtuin 1,Selleck,S1541,NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21
FGIN-1-27,61775,FGIN-1-27,BRD-K09778810,33.0,probe,pilot-set,TSPO,activator of peripheral benzodiazepine receptor/translocator protein,Tocris Bioscience,0658,CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1
FINGOLIMOD,640157,FINGOLIMOD,BRD-K88025533,66.0,FDA,lit-search,S1PR1,inhibitor of sphingosine 1-phosphate receptor,Selleck,S5002,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1
FLUOROURACIL,25344,FLUOROURACIL,BRD-K24844714,130.0,FDA,std-of-care,TYMS,pyrimidine analog; inhibitor of thymidylate synthase,Selleck,S1209,Fc1c[nH]c(=O)[nH]c1=O
FLUVASTATIN,660322,FLUVASTATIN,BRD-A52530402,66.0,FDA,lit-search,HMGCR,inhibitor of HMG-CoA reductase,Tocris Bioscience,3309,CC(C)N1C(\C=C\C(O)CC(O)CC(O)=O)C(c2ccccc12)c1ccc(F)cc1
FORETINIB,628607,FORETINIB,BRD-K03449891,66.0,clinical,kinome,KDR;MET,inhibitor of MET and VEGFR2,Selleck,S1111,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1
FQI-1,102193,FQI-1,BRD-A91658086,33.0,probe,pilot-set,,inhibitor of LSF1-mediated transcription,Boston University,,CCOc1ccccc1C1CC(=O)Nc2cc3OCOc3cc12
FQI-2,609091,FQI-2,BRD-K35498412,33.0,probe,chromatin;pilot-set,,inhibitor of LSF1-mediated transcription,Boston University,,CCOc1ccccc1-c1cc(=O)[nH]c2cc3OCOc3cc12
FSC231,660079,FSC231,BRD-K24784241,270.0,probe,lit-search,PICK1,inhibitor of PDZ domain of protein interacting with PRKCA 1 (PICK1),Specs,AH-034/11366495,CCOC(=O)NC(=O)C(=C\c1ccc(Cl)c(Cl)c1)\C#N
FULVESTRANT,464880,FULVESTRANT,BRD-A85667082,66.0,FDA,std-of-care,ESR1;GPER1,antagonist of the estrogen receptor,Selleck,S1191,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31
FUMONISIN B1,616353,FUMONISIN B1,BRD-A63646118,500.0,probe,pilot-set,CERS1;CERS2;CERS3;CERS4;CERS5;CERS6,inhibitor of ceramide synthase,Cayman,62580,CCCC[C@@H](C)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)[C@H](CC(C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N)OC(=O)C[C@@H](CC(O)=O)C(O)=O
GANT-61,609332,GANT-61,BRD-K09485525,66.0,probe,chromatin;lit-search,,inhibitor of hedgehog signaling pathway,Tocris Bioscience,3191,CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1
GDC-0879,606248,GDC-0879,BRD-K67578145,66.0,probe,kinome,BRAF,inhibitor of BRAF,Selleck,S1104,OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1
GDC-0941,639759,GDC-0941,BRD-K52911425,66.0,clinical,kinome,PIK3CA;PIK3CB;PIK3CD;PIK3CG,inhibitor of PI3K kinase activity,Selleck,S1065,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1
GEFITINIB,52926,GEFITINIB,BRD-K64052750,66.0,FDA,chromatin;CTEP;kinome;std-of-care,AKT1;EGFR,inhibitor of EGFR and AKT1,Selleck,S1025,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1
GEMCITABINE,411863,GEMCITABINE,BRD-K15108141,33.0,FDA,pilot-set;std-of-care,CMPK1;RRM1;TYMS,"inhibitor of DNA replication; inhibitor of ribonucleotide reductase, thymidylate synthetase, and cytidine monophosphate (UMP-CMP) kinase ",Selleck,S1714,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
GMX-1778,411843,GMX-1778,BRD-K47335880,0.3,clinical,pilot-set,NAMPT,inhibitor of nicotinamide phosphoribosyltransferase,WuXi AppTec;Cayman,TH-2360-010-1;11021,Clc1ccc(OCCCCCC\N=C(\NC#N)Nc2ccncc2)cc1
GOSSYPOL,25036,GOSSYPOL,BRD-K19295594,37.0,clinical,CTEP;pilot-set,BCL2;BCL2L1;LDHA;LDHB;LDHC,inhibitor of lactate dehydrogenase; inhibitor of BCL2 family members,ChemDiv Inc.;Sigma-Aldrich,N010-0015;G8761,CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O
GSK-3 INHIBITOR IX,52582,GSK-3 INHIBITOR IX,BRD-K04923131,66.0,probe,kinome,,inhibitor of JAK/STAT signaling,Tocris Bioscience,3194,O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12
GSK-J4,687735,GSK-J4,BRD-K98203492,66.0,probe,chromatin;lit-search,KDM6A;KDM6B,inhibitor of lysine-specific demethylases,Tocris Bioscience,4594,CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1
GSK1059615,606471,GSK1059615,BRD-K06750613,33.0,clinical,kinome,MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG,inhibitor of PI3K and mTOR kinase activity,Selleck,S1360,O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1
GSK2636771,668723,GSK2636771,BRD-K49215523,66.0,clinical,kinome,PIK3CB,inhibitor of PI3K catalytic subunit beta,Active Biochem,A-1230,Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O
GSK4112,660081,GSK4112,BRD-K78667050,66.0,probe,lit-search,NR1D1,antagonist of Rev-ErbAalpha,Tocris Bioscience,3663,CC(C)(C)OC(=O)CN(Cc1ccc(s1)[N+]([O-])=O)Cc1ccc(Cl)cc1
GSK461364,649862,GSK461364,BRD-K92428232,66.0,clinical,kinome,PLK1,inhibitor of polo-like kinase 1 (PLK1),Selleck,S2193,C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F
GSK525762A,660245,GSK525762A,BRD-K08109215,66.0,probe,chromatin;lit-search,BRD2;BRD3;BRD4,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins,EMD Biosciences,401010,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12
GW-405833,375447,GW-405833,BRD-K10705233,130.0,probe,pilot-set,CNR2,partial agonist of cannabinoid receptor 2,Sigma-Aldrich,G1421,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1
GW-843682X,348997,GW-843682X,BRD-K90382497,33.0,probe,kinome;pilot-set,PLK1;PLK3,inhibitor of PLK1 and PLK3,Axon Medchem,1131,COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC
HBX-41108,679843,HBX-41108,BRD-K50501969,66.0,probe,lit-search,USP7,inhibitor of the deubiquitinase activity of USP7,Tocris Bioscience,4285,Clc1ccc-2c(c1)C(=O)c1nc(C#N)c(nc-21)C#N
HC-067047,660083,HC-067047,BRD-K03391209,66.0,probe,lit-search,TRPV4,inhibitor of cation channel TRPV4,Tocris Bioscience,4100,Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F
HLI 373,481311,HLI 373,BRD-K17349619,33.0,probe,pilot-set,MDM2,inhibitor of MDM2,Tocris Bioscience,3503,CN(C)CCCNc1c2ccccc2n(C)c2nc(=O)n(C)c(=O)c12
HYPERFORIN,660327,HYPERFORIN,BRD-A30032852,66.0,clinical,lit-search,TRPC6,agonist of calcium-permeable ion channels,Sigma-Aldrich,H1792,CC(C)C(=O)[C@@]12C(=O)C(CC=C(C)C)C(=O)C(CC=C(C)C)(C[C@H](CC=C(C)C)[C@@]1(C)CCC=C(C)C)C2=O
I-BET151,660206,I-BET151,BRD-K36363294,66.0,probe,chromatin;lit-search,BRD2;BRD3;BRD4,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins,ChemieTek,CT-BET151 .,COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C
IBRUTINIB,660994,IBRUTINIB,BRD-K70301465,66.0,clinical,CTEP;kinome,BTK,inhibitor of Bruton's tyrosine kinase,Selleck,S2680,Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C
IC-87114,55307,IC-87114,BRD-K75430629,66.0,probe,kinome,PIK3CD,inhibitor of PI3K catalytic subunit delta,Selleck,S1268,Cc1ccccc1-n1c(Cn2cnc3c(N)ncnc23)nc2cccc(C)c2c1=O
IFOSFAMIDE,35319,IFOSFAMIDE,BRD-A67097164,66.0,FDA,std-of-care,,DNA alkylator,Selleck,S1302,ClCCNP1(=O)OCCCN1CCCl
IMATINIB,345041,IMATINIB,BRD-K92723993,66.0,FDA,std-of-care,ABL1;BCR;KIT,inhibitor of BCR-ABL1 and c-KIT,Selleck,S2475,CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1
IMPORTAZOLE,46792,IMPORTAZOLE,BRD-A02481876,200.0,probe,pilot-set,KPNB1,inhibitor of importin,Vitas-M Laboratory Ltd.;EMD Biosciences,STK171852;401105,CC(Nc1nc(nc2ccccc12)N1CCCC1)c1ccccc1
INDISULAM,411874,INDISULAM,BRD-K17610631,33.0,clinical,chromatin;pilot-set,CA9,inhibitor of carbonic anhydrase isoform IX,MedKoo Biosciences,,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12
IPR-456,660084,IPR-456,BRD-A76527075,66.0,probe,lit-search;synthesis,PLAUR,inhibitor of the interaction of urokinase receptor with binding partners,ChemDiv Inc.,C090-0424,CC1CC(C)CN(C1)c1cc(Nc2ccccc2C(O)=O)c2C(=O)c3ccccc3-c3onc1c23
ISOEVODIAMINE,594664,ISOEVODIAMINE,BRD-A68631409,33.0,probe,pilot-set,,natural product,Sigma-Aldrich,E3531,CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12
ISOLIQUIRITIGENIN,25393,ISOLIQUIRITIGENIN,BRD-K33583600,33.0,probe,pilot-set,,natural product,MicroSource Discovery Systems Inc.,01504200,Oc1ccc(cc1)\C=C\C(=O)c1ccc(O)cc1O
ISONICOTINOHYDROXAMIC ACID,478694,ISONICOTINOHYDROXAMIC ACID,BRD-K55478147,33.0,probe,chromatin;lit-search;outreach,HDAC6,inhibitor of HDAC6,Stanley Center for Psychiatric Research at the Broad Institute,,ONC(=O)c1ccncc1
ISOX,632907,ISOX,BRD-K69840642,33.0,probe,chromatin;pilot-set,HDAC6,inhibitor of HDAC6,Axon Medchem;Axon Medchem,Axon 1645;1645,CC(C)(C)OC(=O)Nc1ccc(cc1)-c1cc(no1)C(=O)NCCCCCCC(=O)NO
ISOX:BORTEZOMIB (250:1 MOL/MOL),660173,ISOX:BORTEZOMIB (250:1 MOL/MOL),BRD-M94091398,17.0,probe,combination,HDAC6;PSMB1;PSMB2;PSMB5;PSMD1;PSMD2,inhibitor of HDAC6;inhibitor of 26S proteasome,,,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O.CC(C)(C)OC(=O)Nc1ccc(cc1)-c1cc(no1)C(=O)NCCCCCCC(=O)NO
ISTRADEFYLLINE,687694,ISTRADEFYLLINE,BRD-K87774949,33.0,clinical,lit-search,ADORA2A,antagonist of the adenosine A2A receptor,Selleck,S2790,CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O
ITRACONAZOLE,63349,ITRACONAZOLE,BRD-A34817987,17.0,FDA,pilot-set,,anti-fungal agent; inhibitor of hedgehog signaling pathway,Sigma-Aldrich,I6657,CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OCC3COC(Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O
IU1,272805,IU1,BRD-K45841694,66.0,probe,lit-search,USP14,inhibitor of the deubiquitinase activity of USP14,Tocris Bioscience,4088,Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1
JQ-1,616354,JQ-1,BRD-K54606188,66.0,probe,chromatin;lit-search;pilot-set,BRDT,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins,Dana Farber Cancer Institute,,Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1
JQ-1:CARBOPLATIN (1:1 MOL/MOL),660247,JQ-1:CARBOPLATIN (1:1 MOL/MOL),BRD-M11510342,66.0,probe,combination,BRDT,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inducer of DNA damage,,,O=C1O[Pt]OC(=O)C11CCC1.Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1
JQ-1:MK-0752 (1:1 MOL/MOL),660253,JQ-1:MK-0752 (1:1 MOL/MOL),BRD-M94343540,66.0,probe,combination,BRDT;APH1A;NCSTN;PSEN1;PSENEN,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inhibitor of gamma-secretase,,,OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1.Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1
JQ-1:NAVITOCLAX (2:1 MOL/MOL),660252,JQ-1:NAVITOCLAX (2:1 MOL/MOL),BRD-M87479906,50.0,probe,combination,BRDT;BCL2;BCL2L1;BCL2L2,"inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inhibitor of BCL2, BCL-xL, and BCL-W",,,Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
JQ-1:UNC0638 (2:1 MOL/MOL),660129,JQ-1:UNC0638 (2:1 MOL/MOL),BRD-M56714493,50.0,probe,combination,BRDT;EHMT1;EHMT2,inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inhibitor of EHMT2 and GLP methyltransferase,,,Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1.COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1
JQ-1:VORINOSTAT (2:1 MOL/MOL),660823,JQ-1:VORINOSTAT (2:1 MOL/MOL),BRD-M56962220,50.0,probe,combination,BRDT;HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins;inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",,,ONC(=O)CCCCCCC(=O)Nc1ccccc1.Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1
JW-480,660227,JW-480,BRD-K99655327,66.0,probe,lit-search,NCEH1,inhibitor of serine hydrolase enzyme NCEH,Tocris Bioscience,4327,CC(C)c1ccccc1OC(=O)NCCc1ccc2ccccc2c1
JW-55,682993,JW-55,BRD-K53328210,66.0,probe,lit-search,TNKS,inhibitor of tankyrase,ChemBridge Corporation,7667791,COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1
JW-74,676728,JW-74,BRD-K75664313,66.0,probe,lit-search,,inhibitor of WNT signaling,Sigma-Aldrich,SML0227,COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1
KH-CB19,660085,KH-CB19,BRD-K66430217,17.0,probe,kinome,CLK1;CLK4,inhibitor of CDC2-like kinases 1 and 4,Tocris Bioscience,4262,CCOC(=O)c1c(C(=CN)C#N)c2ccc(Cl)c(Cl)c2n1C
KHS101,660819,KHS101,BRD-K78978711,66.0,probe,lit-search,TACC3,"binder of TACC3, a component of the centrosome and mitotic spindle",Sigma-Aldrich,K4019,CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1
KI8751,375560,KI8751,BRD-K47150025,66.0,probe,kinome,KDR;KIT;PDGFRA,"inhibitor of VEGFR2, c-KIT, and PDGFRA",Selleck,S1363,COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC
KO-143,418172,KO-143,BRD-K64642496,130.0,probe,pilot-set,ABCG2,inhibitor of breast cancer resistance protein multidrug transporter (BCRP),Sigma-Aldrich,K2144,COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O
KPT185,660935,KPT185,BRD-K71467466,66.0,probe,outreach,XPO1,inhibitor of exportin 1,Karyopharm Therapeutics,KPT-185-004,COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1
KU 0060648,632119,KU 0060648,BRD-K09499853,33.0,probe,kinome;pilot-set,PRKDC,inhibitor of DNA-dependent protein kinase,Axon Medchem,1584,CCN1CCN(CC(=O)Nc2ccc(-c3cccc4c3oc(cc4=O)N3CCOCC3)c3sc4ccccc4c23)CC1
KU-0063794,606363,KU-0063794,BRD-K67566344,66.0,probe,kinome,MTOR,inhibitor of mTOR,Selleck,S1226,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1
KU-55933,58339,KU-55933,BRD-K25311561,66.0,probe,kinome,ATM,inhibitor of ataxia telangiectasia mutated (ATM),Selleck,S1092,O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1
KU-60019,660411,KU-60019,BRD-K36016295,66.0,probe,kinome,ATM,inhibitor of ataxia telangiectasia mutated (ATM),Selleck,S1570,C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1
KW-2449,660413,KW-2449,BRD-K21718444,66.0,clinical,kinome,AURKA;FLT3,inhibitor of FLT3 and AURKA,Selleck,S2158,O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12
KX2-391,660779,KX2-391,BRD-K29968218,66.0,clinical,kinome,SRC,peptide mimetic; inhibitor of SRC activity in cells,Selleck,S2700,O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1
L-685458,411717,L-685458,BRD-K87317732,37.0,probe,pilot-set,APH1A;NCSTN;PSEN1;PSENEN,inhibitor of gamma-secretase,Sigma-Aldrich,L1790,CC(C)C[C@H](NC(=O)[C@@H](C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C)Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
LAPATINIB,634309,LAPATINIB,BRD-K19687926,66.0,FDA,CTEP;kinome;std-of-care,EGFR;ERBB2,inhibitor of EGFR and HER2,Selleck,S1028,CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1
LBH-589,54210,LBH-589,BRD-K02130563,66.0,clinical,chromatin;outreach,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",Stanley Center for Psychiatric Research at the Broad Institute,,Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1
LE-135,375354,LE-135,BRD-K06593056,66.0,probe,pilot-set,RARB,antagonist of retinoic acid receptor beta,Tocris Bioscience,2021,CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C
LENVATINIB,628639,LENVATINIB,BRD-K39974922,66.0,FDA,lit-search,FLT1;FLT3;KDR;KIT;PDGFRA;PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta",Selleck,S1164,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
LEPTOMYCIN B,660086,LEPTOMYCIN B,BRD-K27624156,66.0,probe,lit-search,XPO1,inhibitor of exportin 1,LC Laboratories,L-6100,CCC(\C=C\[C@@H]1OC(=O)C=C[C@@H]1C)=C\[C@H](C)C\C=C\C(C)=C\[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C\C(O)=O
LINIFANIB,606033,LINIFANIB,BRD-K99749624,66.0,clinical,kinome,FLT1;FLT3;KDR,inhibitor of VEGFRs,Selleck,S1003,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1
LINSITINIB,705300,LINSITINIB,BRD-K08589866,33.0,clinical,CTEP;kinome;pilot-set,IGF1R;INSR,inhibitor of insulin-like growth factor 1 receptor and insulin receptor,Selleck,S1091,CC1(O)CC(C1)c2nc(c3ccc4ccc(nc4c3)c5ccccc5)c6c(N)nccn26
LOMEGUATRIB,660207,LOMEGUATRIB,BRD-K27955832,66.0,clinical,lit-search,MGMT,inhibitor of methylguanine-DNA methyltransferase,Tocris Bioscience,4359,Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1
LOVASTATIN,30620,LOVASTATIN,BRD-A70155556,130.0,FDA,pilot-set,HMGCR,inhibitor of HMG-CoA reductase,AnalytiCon Discovery GmbH,NP-001236,CCC(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC(O)CC(O)CC(O)=O)C12
LRRK2-IN-1,607696,LRRK2-IN-1,BRD-K01436366,66.0,probe,kinome,DCLK1;LRRK2,inhibitor of leucine-rich repeat kinase 2; inhibitor of doublecortin-like kinase,EMD Biosciences,438193,COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1
LY-2157299,660431,LY-2157299,BRD-K78118466,66.0,probe,kinome,TGFBR1,inhibitor of the transforming growth factor beta type 1 receptor,Selleck,S2230,Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O
LY-2183240,375496,LY-2183240,BRD-K37865504,33.0,probe,pilot-set,FAAH,inhibitor of fatty acid amide hydrolase; inhibitor of anandamide uptake,Tocris Bioscience,2452,CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1
MANUMYCIN A,50727,MANUMYCIN A,BRD-K78599730,30.0,probe,pilot-set,FNTA;FNTB,inhibitor of RAS farnesyltransferase,Sigma-Aldrich,M6418,CCCC[C@@H](C)\C=C(C)\C=C(/C)C(=O)NC1=C[C@@](O)(\C=C\C=C\C=C\C(=O)NC2C(=O)CCC2=O)[C@@H]2O[C@@H]2C1=O
MARINOPYRROLE A,666910,MARINOPYRROLE A,BRD-K57261999,66.0,probe,outreach,MCL1,natural product; putative inhibitor of MCL1,Harvard University,,Oc1ccccc1C(=O)c1[nH]c(Cl)c(Cl)c1-n1c(cc(Cl)c1Cl)C(=O)c1ccccc1O
MASITINIB,606143,MASITINIB,BRD-K71035033,66.0,clinical,kinome,KIT;PDGFRA;PDGFRB,"inhibitor of c-KIT, PDGFRA, and PDGFRB",Selleck,S1064,CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1
MDIVI-1,215497,MDIVI-1,BRD-K61128465,66.0,probe,lit-search,DNM1,inhibitor of dynamin 1; inhibitor of mitrochondrial division inhibitor,Tocris Bioscience,3982,COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O
MERCK60,61674,MERCK60,BRD-K04466929,33.0,probe,chromatin;pilot-set,HDAC1;HDAC2,inhibitor of HDAC1 and HDAC2,Stanley Center for Psychiatric Research at the Broad Institute,,CC(=O)Nc1ccc(cc1)C(=O)Nc1cc(ccc1N)-c1cccs1
METHOTREXATE,30371,METHOTREXATE,BRD-K59456551,66.0,FDA,std-of-care,DHFR,inhibitor of dihydrofolate reductase,Selleck,S1210,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
METHYLSTAT,667933,METHYLSTAT,BRD-K52560704,66.0,probe,chromatin;lit-search;outreach,KDM3A;KDM4A;KDM4B;KDM4C;KDM4D,inhibitor of lysine specific demethylases,Colorado State University,,COC(=O)\C=C\C(=O)N(O)CCCCNCc1ccc(COC(=O)Nc2cccc3ccccc23)cc1
MG-132,58948,MG-132,BRD-K60230970,20.0,probe,lit-search,PSMB1;PSMB2;PSMB5;PSMD1;PSMD2,inhibitor of the proteosome,Selleck;Broad Institute of MIT and Harvard,S2619,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O
MGCD-265,628622,MGCD-265,BRD-K56277358,66.0,clinical,kinome,FLT1;FLT3;KDR;MET,inhibitor of c-MET and VEGFRs,Selleck,S1361,Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1
MI-1,185987,MI-1,BRD-K64497429,33.0,probe,lit-search,MEN1,binder of menin; inhibitor of menin-MLL fusion protein,InterBioScreen Ltd.,STOCK3S-35137,CC1(C)CN=C(S1)N1CCN(CC1)c1ncnc2sc3CCCCc3c12
MI-2,687714,MI-2,BRD-K90860366,66.0,probe,chromatin;lit-search;synthesis,MEN1,binder of menin; inhibitor of menin-MLL fusion protein,Broad Institute of MIT and Harvard,,CCCc1cc2c(ncnc2s1)N1CCN(CC1)C1=NCC(C)(C)S1
MITOMYCIN,50732,MITOMYCIN,BRD-K59670716,50.0,FDA,pilot-set;std-of-care,,DNA crosslinker,Sigma-Aldrich,M0440,CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
MK-0752,660332,MK-0752,BRD-K18850819,66.0,clinical,lit-search,APH1A;NCSTN;PSEN1;PSENEN,inhibitor of gamma-secretase,Selleck,S2660,OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1
MK-1775,418167,MK-1775,BRD-K54256913,33.0,clinical,CTEP;kinome;pilot-set,WEE1,inhibitor of WEE1,Axon Medchem,1494,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1
MK-2206,377381,MK-2206,BRD-K68065987,33.0,clinical,chromatin;CTEP;kinome;pilot-set,AKT1,inhibitor of AKT1,Selleck,S1078,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1
ML006,17712,ML006,BRD-K89692698,530.0,probe,pilot-set,S1PR3,agonist of sphingosine 1-phosphate receptor 3,Enamine Ltd.,Z1037336336,C1CN(CCO1)c1nnc(-c2ccccc2)c(n1)-c1ccccc1
ML029,350548,ML029,BRD-K59962020,33.0,probe,chromatin;pilot-set,,inhibitor of antigen receptor-mediated NFkappaB activity,WuXi AppTec,TH02453-034,Cc1cc2nc(NCCCO)n(CC(=O)c3cc(c(O)c(c3)C(C)(C)C)C(C)(C)C)c2cc1C
ML031,96171,ML031,BRD-K38985961,530.0,probe,pilot-set,S1PR2,inhibitor of sphingosine 1-phosphate receptor 2,Enamine Ltd.,Z19746470,Cc1cc(C(=O)CN2C(=O)CCC2=O)c(C)n1Cc1ccccc1
ML050,153820,ML050,BRD-A83255679,66.0,probe,pilot-set,GPER1,antagonist of GPR30,Asinex Ltd.,BAS 02002358,Brc1cc2OCOc2cc1C1Nc2ccccc2C2C=CCC12
ML083,255961,ML083,BRD-K44241590,37.0,probe,pilot-set,PKM,activator of muscle pyruvate kinase,Enamine Ltd.,T6096896,COc1ccc(cc1)S(=O)(=O)N1CCN(CC1)S(=O)(=O)c1ccc2OCCOc2c1
ML162,154846,ML162,BRD-A36275421,33.0,probe,pilot-set,,selectively kills engineered cells expressing mutant HRAS,ChemDiv Inc.,K784-3185,COc1ccc(cc1Cl)N(C(C(=O)NCCc1ccccc1)c1cccs1)C(=O)CCl
ML203,411816,ML203,BRD-K80672993,37.0,probe,pilot-set,PKM,activator of muscle pyruvate kinase (PKM2),WuXi AppTec,TH02357-061,Nc1cccc(c1)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc2OCCOc2c1
ML210,609110,ML210,BRD-K01877528,33.0,probe,pilot-set,,selectively kills engineered cells expressing mutant HRAS,Broad Institute of MIT and Harvard,,Cc1onc(C(=O)N2CCN(CC2)C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)c1[N+]([O-])=O
ML239,609781,ML239,BRD-K01121114,66.0,probe,MLPCN;outreach,,ML239; inhibitor of breast cancer stem cell proliferation,Broad Institute of MIT and Harvard,,Clc1cc(Cl)c(OCC(=O)N\N=C\c2ccc[nH]2)c(Cl)c1
ML258,660314,ML258,BRD-A82720512,66.0,probe,outreach,BCL2L10,inhibitor of BIM-BCL-B interaction,Sanford-Burnham Medical Research Institute,,COc1ccc(CN2c3nnnn3C3C(C2=O)C2(CCCC2)Cc2ccccc32)cc1
ML311,290356,ML311,BRD-A40802033,66.0,probe,outreach,MCL1,inhibitor of MCL1,Eutropics Pharmaceuticals,EU-5346,CCN1CCN(CC1)C(c1ccc(cc1)C(F)(F)F)c1ccc2cccnc2c1O
ML312,434195,ML312,BRD-K70809902,66.0,probe,MLPCN;outreach,SCARB1,"inhibitor of scavenger receptor class B, member 1 (SCARB1)-mediated lipid uptake",Broad Institute of MIT and Harvard,,CC(C)NC(=O)Nc1ccc2O[C@@H](CN(C)S(=O)(=O)c3ccc(Cl)cc3)[C@H](C)CN([C@H](C)CO)C(=O)c2c1
ML320,659682,ML320,BRD-K81491172,66.0,probe,MLPCN;outreach,GSK3B,inhibitor of GSK3 beta,Broad Institute of MIT and Harvard,,COc1ccccc1[C@H]1c2c(NC3=C1C(=O)CC(C)(C)C3)n[nH]c2C(F)(F)F
ML334 DIASTEREOMER,654278,ML334 DIASTEREOMER,BRD-K93367411,130.0,probe,lit-search;synthesis,KEAP1;NFE2L2,inhibitor of KEAP1-NFE2L2 protein-protein interaction,Broad Institute of MIT and Harvard,,OC(=O)[C@@H]1CCCC[C@@H]1C(=O)N1CCc2ccccc2[C@H]1CN1C(=O)c2ccccc2C1=O
MLN2238,632873,MLN2238,BRD-K78659596,33.0,clinical,pilot-set,PSMB5,inhibitor of 20S proteasome at the chymotrypsin-like proteolytic (beta-5) site,Selleck,S2180,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O
MLN2480,687579,MLN2480,BRD-K43410529,66.0,clinical,lit-search,ARAF;BRAF;RAF1,inhibitor of RAF kinases,Active Biochem,A-1192,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F
MOMELOTINIB,660429,MOMELOTINIB,BRD-K87737963,66.0,clinical,kinome,JAK1;JAK2,inhibitor of Janus kinases 1 and 2,Selleck,S2219,O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1
MST-312,411865,MST-312,BRD-K19894101,33.0,probe,chromatin;pilot-set,TERT,inhibitor of telomerase reverse transcriptase,Sigma-Aldrich,M3949,Oc1cccc(C(=O)Nc2cccc(NC(=O)c3cccc(O)c3O)c2)c1O
MYRICETIN,29985,MYRICETIN,BRD-K43149758,66.0,probe,lit-search,,flavonoid antioxidant,Selleck,S2326,Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O
MYRIOCIN,417977,MYRIOCIN,BRD-A76279427,33.0,probe,pilot-set,SPTLC1;SPTLC2;SPTLC3,inhibitor of serine palmitoyltransferase,Sigma-Aldrich,M1177,CCCCCCC(=O)CCCCCC\C=C\C[C@H](O)[C@@H](O)C(N)(CO)C(O)=O
N9-ISOPROPYLOLOMOUCINE,45093,N9-ISOPROPYLOLOMOUCINE,BRD-K71726959,400.0,probe,chromatin;kinome;pilot-set,CCNB1;CDK1;CDK5;CDK5R1,inhibitor of CDK1/cyclin B and CDK5/p35 complexes,Enzo Life Sciences,ALX-270-397-M005,CC(C)n1cnc2c(NCc3ccccc3)nc(NCCO)nc12
NAKITERPIOSIN,417452,NAKITERPIOSIN,BRD-K38264551,33.0,probe,pilot-set,,natural product; inhibitor of microtubule assembly,"University of Texas, Southwestern",,C[C@H]1C[C@@H](OC1=O)[C@@H](O)[C@@H](C(Cl)Cl)c1ccc2[C@@H]3C[C@@H](Br)[C@]45O[C@H](C[C@]4(C)[C@H]3C(=O)c2c1C)CO[C@H]5O
NARCICLASINE,632243,NARCICLASINE,BRD-K06792661,33.0,probe,pilot-set,RHOA,activates cellular activity of RhoA; modulator of Rho/Rho kinase/LIM kinase/cofilin signaling,Sigma-Aldrich,N9789,O[C@H]1C=C2[C@@H](NC(=O)c3c(O)c4OCOc4cc23)[C@H](O)[C@@H]1O
NAVITOCLAX,362342,NAVITOCLAX,BRD-K82746043,33.0,clinical,CTEP;pilot-set,BCL2;BCL2L1;BCL2L2,"inhibitor of BCL2, BCL-xL, and BCL-W",Selleck,S1001,CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
NAVITOCLAX:BIRINAPANT (1:1 MOL/MOL),660172,NAVITOCLAX:BIRINAPANT (1:1 MOL/MOL),BRD-M41956198,33.0,probe,combination,BCL2;BCL2L1;BCL2L2;DIABLO;XIAP,"inhibitor of BCL2, BCL-xL, and BCL-W;SMAC mimetic; inhibitor of inhibitor of apoptosis proteins (IAPs)",,,CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1cc2c(C[C@@H]3C[C@H](O)CN3C(=O)[C@H](CC)NC(=O)[C@H](C)NC)cc(F)cc2[nH]1.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
NAVITOCLAX:GEMCITABINE (1:1 MOL/MOL),660225,NAVITOCLAX:GEMCITABINE (1:1 MOL/MOL),BRD-M68535767,33.0,probe,combination,BCL2;BCL2L1;BCL2L2;CMPK1;RRM1;TYMS,"inhibitor of BCL2, BCL-xL, and BCL-W;inhibitor of DNA replication; inhibitor of ribonucleotide reductase, thymidylate synthetase, and cytidine monophosphate (UMP-CMP) kinase ",,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
NAVITOCLAX:MST-312 (1:1 MOL/MOL),660222,NAVITOCLAX:MST-312 (1:1 MOL/MOL),BRD-M71072276,33.0,probe,combination,BCL2;BCL2L1;BCL2L2;TERT,"inhibitor of BCL2, BCL-xL, and BCL-W;inhibitor of telomerase reverse transcriptase",,,Oc1cccc(C(=O)Nc2cccc(NC(=O)c3cccc(O)c3O)c2)c1O.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
NAVITOCLAX:PIPERLONGUMINE (1:1 MOL/MOL),660284,NAVITOCLAX:PIPERLONGUMINE (1:1 MOL/MOL),BRD-M43334969,33.0,probe,combination,BCL2;BCL2L1;BCL2L2,"inhibitor of BCL2, BCL-xL, and BCL-W;natural product; modulator of ROS levels",,,COc1cc(\C=C\C(=O)N2CCC=CC2=O)cc(OC)c1OC.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
NAVITOCLAX:PLURIPOTIN (1:1 MOL/MOL),660246,NAVITOCLAX:PLURIPOTIN (1:1 MOL/MOL),BRD-M07227555,33.0,probe,combination,BCL2;BCL2L1;BCL2L2;MAPK1;RASAL1,"inhibitor of BCL2, BCL-xL, and BCL-W;promoter of embryonic stem cell self-renewal; inhibitor of Ras-GAP and ERK",,,CN1C(=O)N(Cc2cnc(Nc3cc(C)nn3C)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
NAVITOCLAX:PLX-4032 (1:1 MOL/MOL),660219,NAVITOCLAX:PLX-4032 (1:1 MOL/MOL),BRD-M55709992,33.0,probe,combination,BCL2;BCL2L1;BCL2L2;BRAF,"inhibitor of BCL2, BCL-xL, and BCL-W;inhibitor of BRAF",,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
NAVITOCLAX:SORAFENIB (1:1 MOL/MOL),660283,NAVITOCLAX:SORAFENIB (1:1 MOL/MOL),BRD-M03799014,50.0,probe,combination,BCL2;BCL2L1;BCL2L2;BRAF;FLT3;KDR;RAF1,"inhibitor of BCL2, BCL-xL, and BCL-W;inhibitor of BRAF, CRAF, and VEGFR2",,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
NECROSTATIN-1,375435,NECROSTATIN-1,BRD-A36318220,530.0,probe,pilot-set,RIPK1,inhibitor of receptor-interacting protein kinase 1; inhibitor of the necroptosis cell death pathway,Sigma-Aldrich,N9037,CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O
NECROSTATIN-7,660201,NECROSTATIN-7,BRD-K50145167,66.0,probe,lit-search,,inhibitor of necroptosis,Cayman,10528,Fc1ccc(cc1)-c1n[nH]cc1C=C1SC(=N)N(C1=O)c1nccs1
NECROSULFONAMIDE,677522,NECROSULFONAMIDE,BRD-K64117221,66.0,probe,lit-search,,inhibitor of downstream signaling of RIP3 associated with MLKL,Toronto Research Chemicals,N388600,COc1nccnc1NS(=O)(=O)c1ccc(NC(=O)\C=C\c2ccc(s2)[N+]([O-])=O)cc1
NELARABINE,660391,NELARABINE,BRD-K84466663,66.0,FDA,CTEP;std-of-care,POLA1,deoxyguanosine analog; inhibitor of DNA synthesis,Selleck,S1213,COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
NEOPELTOLIDE,411774,NEOPELTOLIDE,BRD-K62479592,33.0,probe,pilot-set,,inhibitor of cellular respiration,Boston University,,CCC[C@H]1C[C@H](C[C@H](C)C[C@@H]2C[C@H](C[C@H](CC(=O)O1)O2)OC(=O)\C=C/CCc1coc(\C=C/CNC(=O)OC)n1)OC
NERATINIB,418038,NERATINIB,BRD-K85606544,33.0,clinical,kinome;pilot-set,EGFR;ERBB2,inhibitor of EGFR and HER2,WuXi AppTec,HKI-272,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C
NEURONAL DIFFERENTIATION INDUCER III,411733,NEURONAL DIFFERENTIATION INDUCER III,BRD-K53903639,270.0,probe,chromatin;pilot-set,,induction of rat HCN cell differentiation as judged by induction of neuronal reporter neuroD activity,EMD Biosciences,BRD3639,O=C(NC1CC1)c1cc(on1)-c1cccs1
NICLOSAMIDE,32653,NICLOSAMIDE,BRD-K35960502,33.0,FDA,lit-search,STAT3,inhibitor of STAT3 signaling,Sigma-Aldrich,N3510,Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O
NILOTINIB,374749,NILOTINIB,BRD-K81528515,66.0,FDA,kinome;std-of-care,ABL1;BCR;KIT,"inhibitor of ABL1, BCR, and c-KIT",Selleck,S1033,Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F
NINTEDANIB,628601,NINTEDANIB,BRD-K49075727,66.0,clinical,kinome,FGFR1;FGFR2;FGFR3;FLT1;FLT3;KDR;PDGFRA;PDGFRB,"inhibitor of c-KIT, VEGFRs, PDGFRs, and FGFRs",Selleck,S1010,COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1
NPC-26,609058,NPC-26,BRD-K36852164,40.0,probe,pilot-set,,"induces cell death through a non-apoptotic, mitochondrial-dependent mechanism",Columbia University,,CCOC(=O)c1c(NC(=O)c2ccc(s2)[N+]([O-])=O)sc2c1CC(C)(C)NC2(C)C
NSC 74859,411734,NSC 74859,BRD-K40853697,530.0,probe,chromatin;pilot-set,STAT3,inhibitor of STAT3,Selleck,S1155,Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1
NSC19630,580922,NSC19630,BRD-K39706510,66.0,probe,lit-search,WRN,inhibitor of Werner syndrome helicase activity,EMD Biosciences,681467,CCC(=O)OCN1C(=O)C=CC1=O
NSC23766,44503,NSC23766,BRD-A80213327,530.0,probe,pilot-set,RAC1;TIAM1;TRIO,inhibitor of RAC1-GEF interaction; prevents Rac1 activation by Rac-specific guanine nucleotide exchange factors (GEFs) TrioN and Tiam1,Cayman,13196,CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1
NSC30930,182395,NSC30930,BRD-K29711668,66.0,probe,outreach,SRD5A2,inhibitor of steroid 5-alpha reductase,National Cancer Institute Chemotherapeutic Agents Repository,,OC(=O)c1cc2cc(OCc3ccccc3)ccc2[nH]1
NSC48300,594399,NSC48300,BRD-K45748132,66.0,probe,outreach,TASP1,inhibitor of threonine endopeptidase taspase 1,National Cancer Institute Chemotherapeutic Agents Repository,,O[As](O)(=O)c1ccc(Cc2ccc(cc2)[As](O)(O)=O)cc1
NSC632839,375594,NSC632839,BRD-K37392901,33.0,probe,pilot-set,USP13;USP5,inhibitor of ubiquitin isopeptidase,,,Cc1ccc(C=C2CNCC(=Cc3ccc(C)cc3)C2=O)cc1
NSC95397,50715,NSC95397,BRD-K68143200,33.0,probe,pilot-set,CDC25A;CDC25B;CDC25C,inhibitor of cell division cycle 25 phosphatase (CDC25),Sigma-Aldrich,N1786,OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O
NUTLIN-3,411722,NUTLIN-3,BRD-A12230535,150.0,clinical,pilot-set,MDM2,inhibitor of p53-MDM2 interaction,Selleck,S1061,COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1
NVP-231,660331,NVP-231,BRD-A12571627,66.0,probe,kinome,CERK,inhibitor of ceramide kinase,Tocris Bioscience,3960,O=C(Nc1nc2ccc(NC(=O)C34C[C@H]5C[C@H](C[C@H](C5)C3)C4)cc2s1)c1ccccc1
NVP-ADW742,660287,NVP-ADW742,BRD-K15179513,66.0,probe,kinome,IGF1R,inhibitor of insulin-like growth factor 1 receptor,Selleck,S1088,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1
NVP-BEZ235,348992,NVP-BEZ235,BRD-K12184916,17.0,clinical,kinome;outreach;pilot-set,MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG,inhibitor of PI3K and mTOR kinase activity,Spanish National Cancer Research Centre,,Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1
NVP-BSK805,660434,NVP-BSK805,BRD-K02017404,66.0,probe,kinome,JAK2,inhibitor of Janus kinase 2,Selleck,S2686,Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1
NVP-TAE684,606249,NVP-TAE684,BRD-K50140147,66.0,probe,kinome,ALK,inhibitor of ALK and ALK-NPM fusion protein,Selleck,S1108,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1
O-6-BENZYLGUANINE,345712,O-6-BENZYLGUANINE,BRD-K92041145,66.0,clinical,CTEP,MGMT,inhibitor of O(6)-alkylguanine DNA alkyltransferases,Sigma-Aldrich,B2292,Nc1nc(OCc2ccccc2)c2[nH]cnc2n1
OBATOCLAX,606142,OBATOCLAX,BRD-K15600710,66.0,clinical,CTEP,BCL2;BCL2L1;MCL1,"inhibitor of MCL1, BCL2, and BCL-xL",Selleck,S1057,COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1
OLAPARIB,411867,OLAPARIB,BRD-K02113016,150.0,clinical,chromatin;pilot-set,PARP1;PARP2,inhibitor of poly (ADP-ribose) polymerase 1 and 2,Selleck,S1060,Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1
OLIGOMYCIN A,411869,OLIGOMYCIN A,BRD-A81541225,33.0,probe,pilot-set,ATP5L2,inhibitor of mitochondrial ATP synthase,Sigma-Aldrich,75351,CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C
OMACETAXINE MEPESUCCINATE,375219,OMACETAXINE MEPESUCCINATE,BRD-K76674262,66.0,FDA,lit-search,,inhibitor of protein translation by preventing protein elongation,Tocris Bioscience,1416,COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC
OSI-027,660433,OSI-027,BRD-K87124298,66.0,clinical,lit-search,MTOR,inhibitor of mTORC1 and mTORC2,Selleck,S2624,COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12
OSI-930,628620,OSI-930,BRD-K25340465,66.0,clinical,kinome,KDR;KIT,inhibitor of c-KIT and VEGFR2,Selleck,S1220,FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1
OUABAIN,37190,OUABAIN,BRD-K35708212,270.0,probe,lit-search,ATP1A1;ATP1A2;ATP1A3;ATP1A4;ATP1B1;ATP1B2;ATP1B3;ATP1B4,cardiac glycoside; inhibitor of the Na+/K+-ATPase,Tocris Bioscience,1076,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O
OXALIPLATIN,375582,OXALIPLATIN,BRD-M14820059,66.0,FDA,std-of-care,,DNA alkylator; organoplatinum reagent,Selleck,S1224,O=C1O[Pt]2(NC3CCCCC3N2)OC1=O
PAC-1,411832,PAC-1,BRD-K92991072,33.0,probe,pilot-set,CASP3,activator of procaspase-3,Tocris Bioscience,2581,Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1
PACLITAXEL,26956,PACLITAXEL,BRD-A28746609,66.0,FDA,std-of-care,,inhibitor of microtubule assembly,Selleck,S1150,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)C3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1
PALMOSTATIN B,679844,PALMOSTATIN B,BRD-K42137908,66.0,probe,lit-search,LYPLA1,inhibitor of acyl-protein thioesterase 1,EMD Biosciences,178501,CCCCCCCCCC[C@H]1[C@H](CCc2ccc(OC)c(OC)c2)OC1=O
PANDACOSTAT,417098,PANDACOSTAT,BRD-K44741158,33.0,probe,chromatin;pilot-set,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",Harvard Medical School,,ONC(=O)\C=C\c1ccc(cc1)C(=O)N\N=C\c1ccc(O)c(O)c1O
PARBENDAZOLE,28172,PARBENDAZOLE,BRD-K02407574,66.0,probe,pilot-set,,inhibitor of microtubule assembly,Sigma-Aldrich,PH009945,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1
PARTHENOLIDE,411792,PARTHENOLIDE,BRD-K81651477,66.0,probe,pilot-set,,natural product; modulator of ROS; modulator of NF-kappa-B signaling,Tocris Bioscience;Tocris Bioscience,607;0610,C\C1=C\CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1
PAZOPANIB,640265,PAZOPANIB,BRD-K74514084,66.0,FDA,CTEP;kinome;std-of-care,FLT1;FLT3;KDR;KIT;PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFRB",Selleck,S1035,CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1
PD 153035,52133,PD 153035,BRD-K26603252,33.0,probe,kinome,EGFR,inhibitor of EGFR,Selleck,S1079,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC
PD318088,660410,PD318088,BRD-A57798112,66.0,probe,kinome,MAP2K1;MAP2K2,inhibitor of MEK1 and MEK2,Selleck,S1568,OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F
PDMP,58472,PDMP,BRD-K05653692,210.0,probe,pilot-set,UGCG,inhibitor of ceramide glucosyltransferase,Enzo Life Sciences,BML-SL210,CCCCCCCCCC(=O)N[C@H](CN1CCOCC1)[C@H](O)c1ccccc1
PEVONEDISTAT,411809,PEVONEDISTAT,BRD-K67844266,37.0,clinical,pilot-set,NAE1,inhibitor of Nedd-8 activating enzyme,WuXi AppTec,TH02333-012,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12
PF-184,660208,PF-184,BRD-K11593101,66.0,probe,kinome,IKBKB,inhibitor of IKK-2,Tocris Bioscience,4238,C[C@@]1(CO)CN(C[C@]1(C)CO)c1cc(C(=O)Nc2ccc3CCc4c(nn(c4-c3c2)-c2ccc(F)cc2)C(N)=O)c(Cl)cn1
PF-3758309,687953,PF-3758309,BRD-K37764012,66.0,probe,kinome,PAK4,inhibitor of serine/threonine p21-activating kinase 4,Broad Institute of MIT and Harvard,,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1
PF-4800567 HYDROCHLORIDE,688962,PF-4800567 HYDROCHLORIDE,BRD-K43428468,66.0,probe,kinome,CSNK1D;CSNK1E,inhibitor of casein kinase isoforms delta and epsilon,Tocris Bioscience,4281,Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1
PF-543,660073,PF-543,BRD-K79877282,33.0,probe,kinome,SPHK1,inhibitor of sphingosine kinase-1,Pfizer,,Cc1cc(CS(=O)(=O)c2ccccc2)cc(OCc2ccc(CN3CCC[C@@H]3CO)cc2)c1
PF-573228,660075,PF-573228,BRD-K79239947,66.0,probe,kinome,PTK2,inhibitor of focal adhesion kinase,Axon Medchem,Axon 1623,CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1
PF-750,411719,PF-750,BRD-K83213911,270.0,probe,pilot-set,FAAH,inhibitor of fatty acid amide hydrolase,Cayman,10010908,O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1
PHA-793887,640007,PHA-793887,BRD-K64800655,66.0,clinical,chromatin;kinome,CDK1;CDK2;CDK4;CDK5;CDK7;CDK9,inhibitor of cyclin-dependent kinases,Selleck,S1487,CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C
PHLORETIN,24173,PHLORETIN,BRD-K15563106,590.0,probe,pilot-set,SLC5A1,natural product; inhibitor of glucose uptake,Sigma-Aldrich,P7912,Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1
PI-103,411742,PI-103,BRD-K67868012,37.0,probe,kinome;pilot-set,MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG;PRKDC,"inhibitor of DNA-PK, PI3K p110 delta, mTORC1, and catalytic subunits of PI3K",Tocris Bioscience,2930,Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1
PIFITHRIN-ALPHA,50747,PIFITHRIN-ALPHA,BRD-K66874953,230.0,probe,pilot-set,,inhibitor of p53-dependent signaling,Cayman,13326,Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N
PIFITHRIN-MU,375596,PIFITHRIN-MU,BRD-K96799727,33.0,probe,pilot-set,HSPA1A;HSPA1B;HSPA1L;TP53,inhibitor of p53 binding to mitochondria; inhibitor of HSP70,Sigma-Aldrich,P0122,NS(=O)(=O)C#Cc1ccccc1
PIK-93,660774,PIK-93,BRD-K29395450,66.0,probe,kinome,PIK3CG,inhibitor of PI3K catalytic subunit gamma,Selleck,S1489,CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO
PIPERLONGUMINE,39782,PIPERLONGUMINE,BRD-K24132293,33.0,probe,pilot-set,,natural product; modulator of ROS levels,Broad Institute of MIT and Harvard,,COc1cc(cc(OC)c1OC)\C=C\C(=O)N1CCC=CC1=O
PIPERLONGUMINE:MST-312 (1:1 MOL/MOL),660224,PIPERLONGUMINE:MST-312 (1:1 MOL/MOL),BRD-M37545453,33.0,probe,combination,TERT,natural product; modulator of ROS levels;inhibitor of telomerase reverse transcriptase,,,COc1cc(\C=C\C(=O)N2CCC=CC2=O)cc(OC)c1OC.Oc1cccc(C(=O)Nc2cccc(NC(=O)c3cccc(O)c3O)c2)c1O
PITSTOP2,660985,PITSTOP2,BRD-K90570971,66.0,probe,lit-search,CLTA;CLTB;CLTC;CLTCL1,inhibitor of clathrin and clathrin-independent endocytosis,Cellagen Technology,C7487-2,Brc1ccc(cc1)\C=C1/SC(NS(=O)(=O)c2cccc3ccccc23)=NC1=O
PL-DI,609440,PL-DI,BRD-K83336168,66.0,probe,pilot-set,,dimer of piperlongumine; inducer of ROS,Broad Institute of MIT and Harvard,,COc1cc(\C=C\C(=O)N2CCC=CC2=O)cc(OC)c1OCCN(C)CCOc1c(OC)cc(\C=C\C(=O)N2CCC=CC2=O)cc1OC
PLATIN,375395,PLATIN,BRD-K69172251,66.0,FDA,std-of-care,,DNA alkylator; organoplatinum reagent,Selleck,S1166,N[Pt](N)(Cl)Cl
PLURIPOTIN,411833,PLURIPOTIN,BRD-K98538768,33.0,probe,pilot-set,MAPK1;RASAL1,promoter of embryonic stem cell self-renewal; inhibitor of Ras-GAP and ERK,Cayman,10009557,CN1C(=O)N(Cc2cnc(Nc3cc(C)nn3C)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C
PLX-4032,649420,PLX-4032,BRD-K56343971,33.0,FDA,kinome;pilot-set;std-of-care,BRAF,inhibitor of BRAF,Selleck;Sequoia Research Products,S1267;S1267,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F
PLX-4720,606256,PLX-4720,BRD-K16478699,33.0,probe,kinome,BRAF,inhibitor of BRAF,Selleck,S1152,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F
PRIMA-1,50131,PRIMA-1,BRD-K15318909,170.0,probe,pilot-set,TP53,re-activator of the pro-apoptotic activity of mutant p53,Tocris Bioscience,1862,OCC1(CO)N2CCC(CC2)C1=O
PRIMA-1-MET,594663,PRIMA-1-MET,BRD-K49456190,33.0,probe,pilot-set,TP53,re-activator of the pro-apoptotic activity of mutant p53,Tocris Bioscience,3710,COC[C@]1(CO)[N@@]2CC[C@@H](CC2)C1=O
PRL-3 INHIBITOR I,411727,PRL-3 INHIBITOR I,BRD-K09907482,130.0,probe,pilot-set,PTP4A3,inhibitor of phosphatase of regenerating liver-3 (PRL3),Sigma-Aldrich;EMD Biosciences,P0108;539808,Brc1ccc(OCc2ccccc2Br)c(\C=C2\SC(=S)NC2=O)c1
PROCARBAZINE,28183,PROCARBAZINE,BRD-K13032584,66.0,FDA,std-of-care,,inducer of DNA damage,Selleck,S1995,CNNCc1ccc(cc1)C(=O)NC(C)C
PROCHLORPERAZINE,33166,PROCHLORPERAZINE,BRD-K19352500,66.0,FDA,lit-search,DRD2,inhibitor of dopamine receptor D2,Tocris Bioscience,3287,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1
PURMORPHAMINE,52576,PURMORPHAMINE,BRD-K73397362,150.0,probe,pilot-set,SMO,activator of smoothened receptor,Tocris Bioscience;Cayman,10009634;10009634,C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12
PX-12,609124,PX-12,BRD-A56592690,100.0,clinical,pilot-set,TXN,inhibitor of thioredoxin-1,Sigma-Aldrich,M5324,CCC(C)SSc1ncc[nH]1
PYR-41,660202,PYR-41,BRD-K60750172,66.0,probe,lit-search,UBA1,inhibitor of ubiquitin-activating enzyme in cells,Tocris Bioscience;Tocris Bioscience,4088;2978,CCOC(=O)c1ccc(cc1)N1NC(=O)C(=Cc2ccc(o2)[N+]([O-])=O)C1=O
PYRAZOLANTHRONE,44511,PYRAZOLANTHRONE,BRD-K01567962,66.0,probe,kinome,MAPK10;MAPK8;MAPK9,inhibitor of Jun N-terminal kinase (JNK) 1/2/3,Selleck,S1460,O=C1c2ccccc2-c2n[nH]c3cccc1c23
QS-11,609681,QS-11,BRD-K02526760,33.0,probe,pilot-set,ARFGAP1,inhibitor of GTPase activating protein of ARF 1 (ARFGAP1),Tocris Bioscience,3324,OC[C@H](Cc1ccccc1)Nc1nc(Oc2ccc3CCCc3c2)nc2n(Cc3ccc(cc3)-c3ccccc3)cnc12
QUIZARTINIB,640011,QUIZARTINIB,BRD-K93918653,66.0,clinical,kinome,FLT3,inhibtor of VEGFR3,Selleck,S1526,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1
QW-BI-011,362063,QW-BI-011,BRD-K72264770,33.0,probe,chromatin;pilot-set,EHMT2,inhibitor of G9a histone methyltransferase,Broad Institute of MIT and Harvard,,COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1
R428,660993,R428,BRD-K14870255,66.0,probe,kinome,AXL,inhibitor of the tyrosine-protein kinase receptor UFO,Symansis Cell Signaling Science,SY-R428/10,Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1
RAF265,660414,RAF265,BRD-K93123848,66.0,clinical,kinome,BRAF;KDR,ihibitor of VEGFR2 and BRAF,Selleck,S2161,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12
REGORAFENIB,628613,REGORAFENIB,BRD-K16730910,66.0,FDA,kinome,BRAF;KDR;KIT;RET,"inhibitor of BRAF, RET, KIT, and VEGFR2",Selleck,S1178,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1
REPLIGEN 136,628408,REPLIGEN 136,BRD-K47503321,66.0,probe,chromatin;outreach,HDAC3,inhibitor of HDAC3,Stanley Center for Psychiatric Research at the Broad Institute,,Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccc(F)cc1N
RG-108,411831,RG-108,BRD-K89391146,270.0,probe,pilot-set,DNMT1,inhibitor of DNA methyltransferase,Cayman,13302,OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O
RIGOSERTIB,660397,RIGOSERTIB,BRD-K55187425,66.0,clinical,kinome,PIK3CA;PIK3CB;PLK1,inhibitor of polo-like kinase 1; inhibitor of PI3K catalytic subunits alpha and beta,Selleck,S1362,COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1
RITA,375492,RITA,BRD-K00317371,33.0,probe,pilot-set,MDM2;TP53,inhibitor of p53-MDM2 interaction,Tocris Bioscience,2443,OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1
RO4929097,687577,RO4929097,BRD-K22024824,66.0,clinical,CTEP,APH1A;NCSTN;PSEN1;PSENEN,inhibitor of gamma-secretase,Selleck,S1575,CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O
RUXOLITINIB,639450,RUXOLITINIB,BRD-K53972329,66.0,FDA,kinome;std-of-care,JAK1;JAK2,inhibitor of Janus kinases 1 and 2,Selleck,S1378,N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12
SALERMIDE,616352,SALERMIDE,BRD-A67788537,400.0,probe,chromatin;lit-search;pilot-set,SIRT1;SIRT2,inhibitor of sirtuin 1 and sirtuin 2,Cayman,13178,CC(C(=O)Nc1cccc(c1)\N=C\c1c(O)ccc2ccccc12)c1ccccc1
SALERMIDE:PLX-4032 (12:1 MOL/MOL),660269,SALERMIDE:PLX-4032 (12:1 MOL/MOL),BRD-M86771886,220.0,probe,combination,SIRT1;SIRT2;BRAF,inhibitor of sirtuin 1 and sirtuin 2;inhibitor of BRAF,,,CC(C(=O)Nc1cccc(c1)\N=C\c1c(O)ccc2ccccc12)c1ccccc1.CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F
SARACATINIB,606035,SARACATINIB,BRD-K19540840,66.0,clinical,CTEP;kinome,ABL1;SRC,inhibitor of SRC and ABL1,Selleck,S1006,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1
SB-225002,52123,SB-225002,BRD-K61323504,37.0,probe,pilot-set,CXCR2,inhibitor of chemokine receptor 2,ChemDiv Inc.,K815-2000,Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O
SB-431542,50753,SB-431542,BRD-K67298865,66.0,probe,kinome,TGFBR1,inhibitor of the transforming growth factor beta type 1 receptor,Selleck,S1067,NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1
SB-525334,639962,SB-525334,BRD-K37720887,66.0,probe,kinome,TGFBR1,inhibitor of the transforming growth factor beta type 1 receptor,Selleck,S1476,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C
SB-743921,660238,SB-743921,BRD-K62358710,33.0,clinical,lit-search,KIF11,inhibitor of kinesin 11,Selleck,S2182,CC(C)[C@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1
SCH-529074,609062,SCH-529074,BRD-K24376488,33.0,probe,pilot-set,TP53,activator of mutant p53,Broad Institute of MIT and Harvard,,CN(C)CCCNc1nc(CN2CCN(CC2)C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)nc2ccccc12
SCH-79797,375264,SCH-79797,BRD-K17140735,37.0,probe,pilot-set,F2R,antagonist of proteinase-activated receptor 1 (PAR1),Tocris Bioscience,1592,CC(C)c1ccc(Cn2ccc3c2ccc2nc(NC4CC4)nc(N)c32)cc1
SELUMETINIB,348991,SELUMETINIB,BRD-K57080016,270.0,clinical,CTEP;kinome;pilot-set,MAP2K1;MAP2K2,inhibitor of MEK1 and MEK2,Selleck,S1008,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO
SELUMETINIB:BRD-A02303741 (4:1 MOL/MOL),660178,SELUMETINIB:BRD-A02303741 (4:1 MOL/MOL),BRD-M65857522,170.0,probe,combination,MAP2K1;MAP2K2;DOT1L,inhibitor of MEK1 and MEK2;inhibitor of histone methyltransferases,,,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO.CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12
SELUMETINIB:DECITABINE (4:1 MOL/MOL),660249,SELUMETINIB:DECITABINE (4:1 MOL/MOL),BRD-M45217710,170.0,probe,combination,MAP2K1;MAP2K2;DNMT1,inhibitor of MEK1 and MEK2;inhibitor of DNA methyltransferase,,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1.Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO
SELUMETINIB:GDC-0941 (4:1 MOL/MOL),660174,SELUMETINIB:GDC-0941 (4:1 MOL/MOL),BRD-M25329837,170.0,probe,combination,MAP2K1;MAP2K2;PIK3CA;PIK3CB;PIK3CD;PIK3CG,inhibitor of MEK1 and MEK2;inhibitor of PI3K kinase activity,,,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO.CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1
SELUMETINIB:JQ-1 (4:1 MOL/MOL),660177,SELUMETINIB:JQ-1 (4:1 MOL/MOL),BRD-M46138460,170.0,probe,combination,MAP2K1;MAP2K2;BRDT,inhibitor of MEK1 and MEK2;inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins,,,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO.Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1
SELUMETINIB:MK-2206 (8:1 MOL/MOL),660218,SELUMETINIB:MK-2206 (8:1 MOL/MOL),BRD-M34300043,150.0,probe,combination,MAP2K1;MAP2K2;AKT1,inhibitor of MEK1 and MEK2;inhibitor of AKT1,,,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO.NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1
SELUMETINIB:NAVITOCLAX (8:1 MOL/MOL),660248,SELUMETINIB:NAVITOCLAX (8:1 MOL/MOL),BRD-M39644375,150.0,probe,combination,MAP2K1;MAP2K2;BCL2;BCL2L1;BCL2L2,"inhibitor of MEK1 and MEK2;inhibitor of BCL2, BCL-xL, and BCL-W",,,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
SELUMETINIB:PIPERLONGUMINE (8:1 MOL/MOL),660220,SELUMETINIB:PIPERLONGUMINE (8:1 MOL/MOL),BRD-M89326994,150.0,probe,combination,MAP2K1;MAP2K2,inhibitor of MEK1 and MEK2;natural product; modulator of ROS levels,,,COc1cc(\C=C\C(=O)N2CCC=CC2=O)cc(OC)c1OC.Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO
SELUMETINIB:PLX-4032 (8:1 MOL/MOL),660133,SELUMETINIB:PLX-4032 (8:1 MOL/MOL),BRD-M58862563,150.0,probe,combination,MAP2K1;MAP2K2;BRAF,inhibitor of MEK1 and MEK2;inhibitor of BRAF,,,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO.CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F
SELUMETINIB:TRETINOIN (2:1 MOL/MOL),660175,SELUMETINIB:TRETINOIN (2:1 MOL/MOL),BRD-M45185124,200.0,probe,combination,MAP2K1;MAP2K2;RARA;RARB;RARG,inhibitor of MEK1 and MEK2;agonist of retinoid acid receptors,,,CC(=C/CO)\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C.Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO
SELUMETINIB:UNC0638 (4:1 MOL/MOL),660281,SELUMETINIB:UNC0638 (4:1 MOL/MOL),BRD-M39460218,170.0,probe,combination,MAP2K1;MAP2K2;EHMT1;EHMT2,inhibitor of MEK1 and MEK2;inhibitor of EHMT2 and GLP methyltransferase,,,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO.COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1
SELUMETINIB:VORINOSTAT (8:1 MOL/MOL),660176,SELUMETINIB:VORINOSTAT (8:1 MOL/MOL),BRD-M98616540,150.0,probe,combination,MAP2K1;MAP2K2;HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of MEK1 and MEK2;inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",,,ONC(=O)CCCCCCC(=O)Nc1ccccc1.Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO
SEMAGACESTAT,660341,SEMAGACESTAT,BRD-K65592642,66.0,clinical,lit-search,APH1A;NCSTN;PSEN1;PSENEN,inhibitor of gamma-secretase,Selleck,S1594,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1c2ccccc2CCN(C)C1=O
SERDEMETAN,418164,SERDEMETAN,BRD-K60219430,33.0,clinical,pilot-set,MDM2,inhibitor of MDM2,Axon Medchem,1538,C(Cc1c[nH]c2ccccc12)Nc1cccc(Nc2ccncc2)c1
SERDEMETAN:SCH-529074 (1:1 MOL/MOL),660132,SERDEMETAN:SCH-529074 (1:1 MOL/MOL),BRD-M28943608,33.0,probe,combination,MDM2;TP53,inhibitor of MDM2;activator of mutant p53,,,C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1.CN(C)CCCNc1nc(CN2CCN(CC2)C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)nc2ccccc12
SGX-523,635882,SGX-523,BRD-K19477839,66.0,clinical,kinome,MET,inhibitor of MET,Selleck,S1112,Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1
SID 26681509,411731,SID 26681509,BRD-K08417745,300.0,probe,pilot-set,CTSL1,inhibitor of cathepsin L,Tocris Bioscience,3625,CCc1ccccc1NC(=O)CSC(=O)NNC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)OC(C)(C)C
SILDENAFIL,27872,SILDENAFIL,BRD-K50128260,530.0,FDA,pilot-set,PDE5A,inhibitor of phosphodiesterase 5A,Toronto Research Chemicals,S435000,CCCc1nn(C)c2C(=O)NC(=Nc12)c3cc(ccc3OCC)S(=O)(=O)N4CCN(C)CC4
SILMITASERTIB,660421,SILMITASERTIB,BRD-K81458380,66.0,clinical,kinome,CSNK2A1;CSNK2A2,inhibitor of casein kinase 2,Selleck,S2248,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21
SIMVASTATIN,27894,SIMVASTATIN,BRD-K22134346,33.0,FDA,pilot-set,HMGCR,inhibitor of HMG-CoA reductase,Tocris Bioscience,1965,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12
SIROLIMUS,56703,SIROLIMUS,BRD-K84937637,33.0,FDA,kinome,MTOR,inhibitor of mTOR,Selleck,S1039,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
SIROLIMUS:BORTEZOMIB (250:1 MOL/MOL),660134,SIROLIMUS:BORTEZOMIB (250:1 MOL/MOL),BRD-M02488208,17.0,probe,combination,MTOR;PSMB1;PSMB2;PSMB5;PSMD1;PSMD2,inhibitor of mTOR;inhibitor of 26S proteasome,,,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O.CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O
SITAGLIPTIN,58442,SITAGLIPTIN,BRD-K19416115,66.0,FDA,outreach,DPP4,inhibitor of dipetidyl peptidase-4,Selleck,S4002,N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F
SJ-172550,416777,SJ-172550,BRD-K93095519,33.0,probe,pilot-set,MDM2;TP53,inhibitor of p53-MDM2 interaction,Tocris Bioscience,3929,CCOc1cc(cc(Cl)c1OCC(=O)OC)\C=C1C(=O)N(N=C/1C)c1ccccc1
SKEPINONE-L,688799,SKEPINONE-L,BRD-K83607951,66.0,probe,kinome,MAPK14,inhibitor of p38 MAPK,Broad Institute of MIT and Harvard,,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1
SKI-II,375366,SKI-II,BRD-K20755323,130.0,probe,kinome;pilot-set,SPHK1,inhibitor of sphingosine kinase 1,Cayman,10009222,Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1
SMER-3,660286,SMER-3,BRD-K92960067,66.0,probe,lit-search,CUL1;SKP1,inhibitor of E3-ubiquitin ligase,Tocris Bioscience,4375,O=C1c2ccccc2-c2nc3nonc3nc12
SN-38,375637,SN-38,BRD-A36630025,1.3,probe,pilot-set,TOP1,metabolite of irinotecan; inhibitor of topoisomerase I,Tocris Bioscience,2684,CCc1c2Cn3c(cc4c(COC(=O)C4(O)CC)c3=O)-c2nc2ccc(O)cc12
SNS-032,606254,SNS-032,BRD-K43389698,66.0,clinical,chromatin;kinome;lit-search,CDK16;CDK17;CDK2;CDK7;CDK9;CDKL5,inhibitor of cyclin-dependent kinases,Selleck,S1145,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1
SNX-2112,362338,SNX-2112,BRD-K71281111,37.0,probe,pilot-set,HSP90AA1;HSP90B1,inhibitor of HSP90alpha and HSP90beta,Broad Institute of MIT and Harvard,,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1
SNX-2112:BORTEZOMIB (250:1 MOL/MOL),660251,SNX-2112:BORTEZOMIB (250:1 MOL/MOL),BRD-M68452404,17.0,probe,combination,HSP90AA1;HSP90B1;PSMB1;PSMB2;PSMB5;PSMD1;PSMD2,inhibitor of HSP90alpha and HSP90beta;inhibitor of 26S proteasome,,,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O.CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1
SORAFENIB,349006,SORAFENIB,BRD-K23984367,66.0,FDA,CTEP;kinome;std-of-care,BRAF;FLT3;KDR;RAF1,"inhibitor of BRAF, CRAF, and VEGFR2",Cayman,10009644,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1
SOTRASTAURIN,661032,SOTRASTAURIN,BRD-K16761703,66.0,clinical,kinome,PRKCB,inhibitor of protein kinase C beta,Axon Medchem,1635,CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1
SPAUTIN-1,657183,SPAUTIN-1,BRD-K84964099,66.0,probe,lit-search,USP10;USP13,inhibitor of the deubiquitinase activity of USP13 and USP10,Broad Institute of MIT and Harvard,,Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1
SR-II-138A,411770,SR-II-138A,BRD-K11172604,33.0,probe,pilot-set,EIF4A2;EIF4E;EIF4G1,silvestrol analog; inhibits translation by modulating the eIF4F complex,Boston University,,CON(C)C(=O)[C@H]1[C@@H](O)[C@@]2(O)c3c(O[C@]2([C@@H]1c1ccccc1)c1ccc(OC)cc1)cc(OC)cc3OC
SR1001,660317,SR1001,BRD-K47981327,66.0,probe,chromatin;lit-search,RORA;RORC,synthetic ROR ligand; suppressor of TH17 differentiation,Cayman,10922,CC(=O)Nc1nc(C)c(s1)S(=O)(=O)Nc1ccc(cc1)C(O)(C(F)(F)F)C(F)(F)F
SR8278,668858,SR8278,BRD-A02904414,66.0,probe,lit-search,NR1D1,antagonist of Rev-ErbAalpha,EMD Biosciences,EMB-5547,CCOC(=O)C1Cc2ccccc2CN1C(=O)c1ccc(SC)s1
SRT-1720,411820,SRT-1720,BRD-K53855319,37.0,probe,chromatin;pilot-set,SIRT1,activator of sirtuin-1,WuXi AppTec,TH02370-053,O=C(Nc1cc(CN2CCNCC2)cc(c1)-c1nc2ccccc2[nH]1)c1cnc2ccccc2n1
STAUROSPORINE,50769,STAUROSPORINE,BRD-K17953061,3.3,probe,lit-search,,inhibitor of multiple kinases,Sigma-Aldrich;LC Laboratories,S4400;S-9300,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13
STEMREGENIN 1,609063,STEMREGENIN 1,BRD-K36739687,66.0,probe,chromatin;lit-search;outreach,AHR,inhibitor of aryl hydrocarbon receptor,BioVision,1967-5,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12
STF-31,652975,STF-31,BRD-K22477529,66.0,probe,lit-search;synthesis,NAMPT,inhibitor of nicotinamide phosphoribosyltransferase,Broad Institute of MIT and Harvard,,CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1
SU11274,606586,SU11274,BRD-K02965346,66.0,probe,kinome,MET,inhibitor of MET,Selleck,S1080,CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1
SUNITINIB,374750,SUNITINIB,BRD-K42828737,66.0,FDA,CTEP;kinome,FLT1;FLT3;KDR;KIT;PDGFRA;PDGFRB,"inhibitor of VEGFRs, c-KIT, and PDGFR alpha and beta",Selleck,S1042,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C
SZ4TA2,688138,SZ4TA2,BRD-K55125219,66.0,probe,lit-search,BCL2L1,inhibitor of BCL-xL,Broad Institute of MIT and Harvard,,CC1(C)CCN(CC1)c1ccc(cc1)C(=O)NS(=O)(=O)c1ccc(NCCSc2ccccc2)c(c1)[N+]([O-])=O
TACEDINALINE,54200,TACEDINALINE,BRD-K52313696,33.0,probe,chromatin;lit-search;outreach,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",Stanley Center for Psychiatric Research at the Broad Institute,,CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N
TACROLIMUS,50737,TACROLIMUS,BRD-K69608737,74.0,FDA,pilot-set,PPP3CA;PPP3CB;PPP3CC;PPP3R1;PPP3R2,inhibitor of calcineurin,Selleck,S5003,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
TAMATINIB,417818,TAMATINIB,BRD-K20285085,33.0,clinical,CTEP;kinome;pilot-set,SYK,inhibitor of spleen tyrosine kinase,Selleck,S2194,COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC
TAMOXIFEN,26972,TAMOXIFEN,BRD-K93754473,100.0,FDA,chromatin;std-of-care,ESR1;ESR2,modulator of estrogen receptors,Sigma-Aldrich,T5648,CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1
TANDUTINIB,464458,TANDUTINIB,BRD-K89162000,66.0,clinical,CTEP;kinome,FLT3;KIT,inhibitor of c-KIT and VEGFR3,Selleck,S1043,COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1
TANESPIMYCIN,50134,TANESPIMYCIN,BRD-K81473043,33.0,clinical,pilot-set,HSP90AA1,inhibitor of HSP90,Tocris Bioscience,1515,CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O
TANESPIMYCIN:BORTEZOMIB (250:1 MOL/MOL),660221,TANESPIMYCIN:BORTEZOMIB (250:1 MOL/MOL),BRD-M09675615,17.0,probe,combination,HSP90AA1;PSMB1;PSMB2;PSMB5;PSMD1;PSMD2,inhibitor of HSP90;inhibitor of 26S proteasome,,,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O.CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O
TANESPIMYCIN:GEMCITABINE (1:1 MOL/MOL),660216,TANESPIMYCIN:GEMCITABINE (1:1 MOL/MOL),BRD-M41695494,33.0,probe,combination,HSP90AA1;CMPK1;RRM1;TYMS,"inhibitor of HSP90;inhibitor of DNA replication; inhibitor of ribonucleotide reductase, thymidylate synthetase, and cytidine monophosphate (UMP-CMP) kinase ",,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1.CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O
TEMOZOLOMIDE,351043,TEMOZOLOMIDE,BRD-A94153989,66.0,FDA,std-of-care,,DNA alkylator,Selleck,S1237,CN1N=Nc2c(ncn2C1=O)C(=O)N
TEMSIROLIMUS,660358,TEMSIROLIMUS,BRD-K08177763,66.0,FDA,CTEP;kinome;std-of-care,MTOR,inhibitor of mTOR,Selleck,S1044,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO
TENIPOSIDE,27871,TENIPOSIDE,BRD-A35588707,33.0,FDA,pilot-set,TOP2A;TOP2B,inhibitor of topoisomerase II,MicroSource Discovery Systems Inc.,01504094,COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12
TG-100-115,606470,TG-100-115,BRD-K64785675,66.0,clinical,kinome,PIK3CD;PIK3CG,inhibitor of PI3K catalytic subunits delta and gamma,Selleck,S1352,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1
TG-101348,411808,TG-101348,BRD-K12502280,37.0,clinical,kinome;pilot-set,JAK2,inhibitor of Janus kinase 2,Selleck,S2736,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C
TGX-221,606356,TGX-221,BRD-A41692738,66.0,probe,kinome,PIK3CB,inhibitor of PI3K catalytic subunit beta,Selleck,S1169,CC(Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1
THALIDOMIDE,24197,THALIDOMIDE,BRD-A93255169,66.0,FDA,CTEP;kinome,CRBN,immunomodulatory drug; binder of cereblon,Selleck,S1193,O=C1N(C2CCC(=O)NC2=O)C(=O)c2ccccc12
TIGECYCLINE,659993,TIGECYCLINE,BRD-A34462049,66.0,FDA,lit-search;outreach,,analog of tetracycline,Selleck;Harvard University,S1403,CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(NC(=O)CNC(C)(C)C)c(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C
TIPIFARNIB-P1,417417,TIPIFARNIB-P1,BRD-K63195589,33.0,clinical,pilot-set,FNTA,inhibitor of farnesyltransferase,WuXi AppTec;Selleck,TH02436-025 - P1;S1453,Cn1cncc1[C@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1
TIPIFARNIB-P2,417416,TIPIFARNIB-P2,BRD-K62965247,33.0,probe,pilot-set,FNTA,inhibitor of farnesyltransferase,WuXi AppTec,TH02436-025 - P2,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1
TIVANTINIB,687406,TIVANTINIB,BRD-K33379087,66.0,clinical,CTEP;kinome,MET,inhibitor of MET; inhibitor of microtubule assembly,Active Biochem,A-1109,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23
TIVOZANIB,418170,TIVOZANIB,BRD-K53414658,33.0,clinical,pilot-set,FLT1;FLT3;KDR,inhibitor of VEGFRs,Selleck,S1207,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
TOPOTECAN,44580,TOPOTECAN,BRD-K55696337,66.0,FDA,std-of-care,TOP1,inhibitor of topoisomerase I,Selleck,S1231,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O
TOSEDOSTAT,417987,TOSEDOSTAT,BRD-K92241597,270.0,clinical,pilot-set,ANPEP;LAP3;NPEPPS,"inhibitor of leucine aminopeptidase 3 (LAP), puromycin-sensitive aminopeptidase (PuSA), and aminopeptidase N",Selleck,S1522,CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1
TPCA-1,375564,TPCA-1,BRD-K51575138,66.0,probe,chromatin;outreach,IKBKB,inhibitor of IKK-2,Tocris Bioscience,2559,NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1
TRAMETINIB,687418,TRAMETINIB,BRD-K12343256,66.0,clinical,CTEP;kinome,MAP2K1;MAP2K2,inhibitor of MEK1 and MEK2,Selleck,S2673,CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O
TRETINOIN,23151,TRETINOIN,BRD-K64634304,130.0,FDA,chromatin;pilot-set,RARA;RARB;RARG,agonist of retinoid acid receptors,Sigma-Aldrich;Sigma-Aldrich,R2625;R2625-50MG,CC(=CC=CC(=CC(=O)O)C)C=CC1=C(C)CCCC1(C)C
TRETINOIN:CARBOPLATIN (2:1 MOL/MOL),660181,TRETINOIN:CARBOPLATIN (2:1 MOL/MOL),BRD-M31706333,100.0,probe,combination,RARA;RARB;RARG,agonist of retinoid acid receptors;inducer of DNA damage,,,O=C1O[Pt]OC(=O)C11CCC1.CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/CO
TRETINOIN:NAVITOCLAX (4:1 MOL/MOL),660179,TRETINOIN:NAVITOCLAX (4:1 MOL/MOL),BRD-M74379094,83.0,probe,combination,RARA;RARB;RARG;BCL2;BCL2L1;BCL2L2,"agonist of retinoid acid receptors;inhibitor of BCL2, BCL-xL, and BCL-W",,,CC(=C/CO)\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
TRIAZOLOTHIADIAZINE,385240,TRIAZOLOTHIADIAZINE,BRD-K05402890,66.0,probe,pilot-set,PDE4A;PDE4B;PDE4D,inhibitor of phosphdiesterase 4A/B/D,WuXi AppTec,TH02420-017,COc1ccc(OC)c(c1)-c1nnc2SCC(=Nn12)c1ccc(OC)c(OC)c1
TRIFLUOPERAZINE,26914,TRIFLUOPERAZINE,BRD-K89732114,33.0,FDA,pilot-set,DRD2,antagonist of dopamine receptor D2,Toronto Research Chemicals,T779200,CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1
TRIPTOLIDE,411720,TRIPTOLIDE,BRD-A13122391,0.3,clinical,pilot-set,,natural product; inhibitor of RNA polymerase II,Sigma-Aldrich,T3652,CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3CC3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O
TUBASTATIN A,411749,TUBASTATIN A,BRD-K00627859,33.0,probe,chromatin;pilot-set,HDAC6,inhibitor of tubulin deacetylase activity of HDAC6,Stanley Center for Psychiatric Research at the Broad Institute,,CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO
TW-37,609596,TW-37,BRD-K28360340,33.0,probe,pilot-set,BCL2;BCL2L1,inhibitor of BCL2 and BCL-xL,Tocris Bioscience,4038,CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O
UNC0321,635576,UNC0321,BRD-K74236984,33.0,probe,chromatin;pilot-set,EHMT2,inhibitor of G9a histone methyltransferase,Cayman,10582,COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1
UNC0638,594665,UNC0638,BRD-K86856088,33.0,probe,chromatin;lit-search;pilot-set,EHMT1;EHMT2,inhibitor of EHMT2 and GLP methyltransferase,Tocris Bioscience,4343,COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1
UNC0638:NAVITOCLAX (1:1 MOL/MOL),660270,UNC0638:NAVITOCLAX (1:1 MOL/MOL),BRD-M97749165,33.0,probe,combination,EHMT1;EHMT2;BCL2;BCL2L1;BCL2L2,"inhibitor of EHMT2 and GLP methyltransferase;inhibitor of BCL2, BCL-xL, and BCL-W",,,COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
VAF-347,659226,VAF-347,BRD-K96335988,66.0,probe,lit-search;synthesis,AHR,inhibitor of aryl hydrocarbon receptor,Broad Institute of MIT and Harvard,,FC(F)(F)c1ccc(Nc2nccc(n2)-c2cccc(Cl)c2)cc1
VALDECOXIB,32372,VALDECOXIB,BRD-K12994359,600.0,FDA,pilot-set,PTGS2,inhibitor of cyclooxygenase-2 (COX2),Sigma-Aldrich;Sigma-Aldrich,PA0179;PZ0179,Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1
VANDETANIB,349002,VANDETANIB,BRD-K77625799,66.0,FDA,kinome;std-of-care,EGFR;KDR,inhibitor of VEGFR2 and EGFR,Selleck,S1046,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1
VELIPARIB,606034,VELIPARIB,BRD-K87142802,33.0,clinical,chromatin;CTEP;pilot-set,PARP1;PARP2,inhibitor of poly (ADP-ribose) polymerase 1 (PARP1) and 2 (PARP2),Selleck,S1004,C[C@@]1(CCCN1)c1nc2c(cccc2[nH]1)C(N)=O
VER-155008,411815,VER-155008,BRD-K32330832,37.0,probe,pilot-set,HSPA1A;HSPA1B;HSPA1L,inhibitor of HSP70,WuXi AppTec,TH02357-035,Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12
VINCRISTINE,62602,VINCRISTINE,BRD-K82109576,130.0,FDA,std-of-care,,inhibitor of mictrotubule assembly,Selleck,S1241,CC[C@]1(O)C[C@@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC
VORAPAXAR,660136,VORAPAXAR,BRD-K93442924,66.0,clinical,lit-search,F2R,antagonist of proteinase-activated receptor 1 (PAR1),Axon Medchem,1755,CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1
VORINOSTAT,56554,VORINOSTAT,BRD-K81418486,33.0,FDA,chromatin;CTEP;pilot-set;std-of-care,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8",Toronto Research Chemicals,S688700,ONC(=O)CCCCCCC(=O)Nc1ccccc1
VORINOSTAT:CARBOPLATIN (1:1 MOL/MOL),660131,VORINOSTAT:CARBOPLATIN (1:1 MOL/MOL),BRD-M09269305,66.0,probe,combination,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8;inducer of DNA damage",,,O=C1O[Pt]OC(=O)C11CCC1.ONC(=O)CCCCCCC(=O)Nc1ccccc1
VORINOSTAT:NAVITOCLAX (4:1 MOL/MOL),660301,VORINOSTAT:NAVITOCLAX (4:1 MOL/MOL),BRD-M23798888,33.0,probe,combination,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8;BCL2;BCL2L1;BCL2L2,"inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8;inhibitor of BCL2, BCL-xL, and BCL-W",,,ONC(=O)CCCCCCC(=O)Nc1ccccc1.CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
VU0155056,660119,VU0155056,BRD-K31406481,66.0,probe,lit-search,PLD1;PLD2,inhibitor of phospholipase D1/D2,"Avanti Polar Lipids, Inc.",857370P,O=C(NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc2ccccc2c1
VX-680,340501,VX-680,BRD-K59369769,66.0,clinical,pilot-set,AURKA;AURKB;AURKC,inhibitor of aurora kinases,Selleck,S1048,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1
WAY-362450,660821,WAY-362450,BRD-K54640016,66.0,probe,chromatin;lit-search,NR1H4,agonist of farnesoid X receptor,Axon Medchem,1749,CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1
WP1130,660432,WP1130,BRD-K43644456,66.0,probe,lit-search,UCHL5;USP14;USP5;USP9X,"inhibitor of the deubiquitinase activity of USP9X, USP5, USP14, and UCH37",Selleck,S2243,CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1
WZ4002,640366,WZ4002,BRD-K72420232,33.0,probe,kinome,EGFR,inhibitor of EGFR targeting T790M resistance,Selleck,S1173,COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1
WZ8040,628614,WZ8040,BRD-K81728688,66.0,probe,kinome,EGFR,inhibitor of EGFR targeting T790M resistance,Selleck,S1179,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1
XL765,660304,XL765,BRD-K75308783,66.0,clinical,kinome,MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG;PRKDC,inhibitor of mTOR and PI3K kinase acitivities,Selleck,S1523,COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1
YK 4-279,632103,YK 4-279,BRD-A62182663,33.0,probe,chromatin;pilot-set,DHX9;ERG;ETV1,inhibitor of RNA helicase A (RHA) binding to EWS-FLI1; inhibitor of ERG and ETV1 activity,Tocris Bioscience,4067,COc1ccc(cc1)C(=O)CC1(O)C(=O)Nc2c1c(Cl)ccc2Cl
YL54,651298,YL54,BRD-K58306044,66.0,probe,outreach,,stapled helical peptide,Harvard University,,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CCNC(C)=O)C(=O)N[C@]1(C)CCC\C=C/CCC[C@@](C)(NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC1=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
YM-155,417979,YM-155,BRD-K76703230,1.0,clinical,pilot-set,BIRC5,inhibitor of survivin expression,Active Biochem,A-1061,COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C
ZEBULARINE,411739,ZEBULARINE,BRD-A01145011,590.0,probe,chromatin;pilot-set,DNMT1,inhibitor of DNA methyltransferases,Tocris Bioscience,2293,OC[C@H]1O[C@H](C(O)[C@H]1O)n1cccnc1=O
ZSTK474,606144,ZSTK474,BRD-K63068307,66.0,clinical,kinome,PIK3CB;PIK3CD;PIK3CG,"inhibitor of PI3K catalytic subunits beta, delta, and gamma",Selleck,S1072,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1
